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ABSTRACT OF DISSERTATION
AN INVESTIGATION OF PERINATAL POLYCHLORINATED BIPHENYL 
EXPOSURE ON BODY COMPOSITION AND GLUCOSE HOMEOSTASIS
 
Recent advancements have uncovered environmental contributions to obesity and 
diabetes etiology. In fact, perinatal malnutrition resulting in low birth weight (LBW) has 
been shown to correlate with later life obesity and impaired glucose tolerance in aged 
offspring.  LBW can result from a myriad of developmental perturbations including 
macronutrient restriction, hypoxia, maternal stress and toxin exposure. 
Polychlorinated biphenyls (PCBs) are ubiquitous environmental pollutants that 
bioaccumulate in the food chain resulting in dietary exposure in humans.  Maternal and 
cord blood PCB levels are inversely associated with birth weight, and recent studies 
indicate that perinatal exposures to PCBs contribute to gender-specific obesity 
development in children. PCBs have also been shown to enter breast milk resulting in 
direct exposure in early postnatal life. Therefore, we hypothesized that perinatal PCB 
exposure cause developmental blight resulting in decreased birth weight and increased 
adiposity and glucose intolerance with aging.  We found that mice perinatally exposed to 
PCBs did not differ in birth weight, but exhibited sex-specific effects on adiposity. 
Females perinatally exposed to PCBs were significantly more obese at 7 weeks of age 
while male offspring exhibited no difference in fat mass but had decreased lean mass 
compared to controls.  With aging, the differences in females dissipated while the male 
offspring decreased lean mass persisted.  Male offspring perinatally exposed to PCBs 
displayed impaired glucose tolerance at 7 weeks of age but normalized over time, while 
the females were glucose intolerant only after 6 months of age. This impairment of 
glucose tolerance was not attributed to insulin resistance.   These data illustrate time-
dependent and sex-specific perturbations of maternal PCB exposure on offspring body 
composition and glucose homeostasis.  
As the liver is a major facilitator in glucose homeostasis and xenobiotic 
detoxification, we investigated PCB-induced alterations in hepatic gene expression and 
 
found attenuated expression of glycolytic genes and increased expression of detoxifying 
and antioxidant genes in both PCB-exposed maternal and offspring livers. Taken
together, these data demonstrate a role for perinatal pollutant exposure in the etiology of 
glucose intolerance.  Further studies are required to elucidate the mechanisms causing 
sex-specific modulation of body composition and glucose intolerance.
Keywords: polychlorinated biphenyls, obesity, diabetes, developmental programming, 
environmental pollutants
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CHAPTER 1
INTRODUCTION
1.1 Diabetes
1.1.1 Diabetes in America and the Clinic Diabetes is a chronic noncommunicable
disease characterized by hyperglycemia beyond a normal range.  A hormone, insulin, is 
secreted by the pancreas in response to a meal and signals for glucose transporters to be 
translocated to cell surface of skeletal muscles and adipose tissue to facilitate transport 
into the cells from the periphery.  By doing so, blood glucose levels decrease.  The liver, 
too, takes up glucose thereby decreasing blood glucose levels. Diabetes is an inability to 
modulate blood glucose by either lack of insulin secretion, an inefficient response to 
insulin by peripheral tissues, but most commonly, a combination of the two.  Diabetes is 
clinically characterized as having fasted blood glucose levels over 126 mg/dL or blood 
glucose of over 200 mg/dL following a 2 hour oral glucose challenge while normal levels 
are <100 and <140 mg/dL, respectively [1, 2].  Blood glucose levels above normal but 
below diabetes criteria are called prediabetes, and patients are characterized as having 
either impaired fasting glucose (IFG) or impaired glucose tolerance (IGT).  Prediabetics 
have an increased risk of developing overt diabetes if lifestyle interventions are not 
adopted [2].
Diabetes affects over 340 million people worldwide and 25 million of those are in 
the United States.  In The United States, the prevalence of diabetes has increased over the 
past 20 years [1, 3].  Over 8% of Americans have diabetes and it is estimated that 1 in 3 
Americans born after the year 2000 will develop diabetes in their lifetime [1, 4].  This 
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disease has cost the United States an estimated $245 billion dollars in 2012, up 39% from 
2007, and $174 billion dollars are from direct medical costs [5]. Moreover, diabetes is 
associated with various serious comorbidities such as hypertension, stroke, heart disease 
and renal failure.  In addition, it is the leading cause of non-traumatic limb amputations, 
and a major cause of blindness [1].
There are two types of diabetes, Type 1 diabetes, or insulin-dependent diabetes, 
which occurs primarily in children and is an autoimmune disease causing destruction of 
insulin- -cells.  Treatment is administration of insulin via 
subcutaneous injection [2].  The second and more prevalent type is type 2 diabetes 
mellitus (T2DM), or insulin-independent diabetes.  T2DM is different from Type 1 in 
that it is not caused by immunological -cell destruction, but rather by an inability of 
insulin to solicit its normal glucoregulatory response [6].  This inability of insulin to 
influence glucose homeostasis is referred to as insulin resistance.  To compensate, the 
-cells hypertrophy in an attempt to secrete enough insulin to elicit an 
-cell destruction [7]. Ninety-five 
to 99% of all diabetes cases in the United States are T2DM, and there are behaviors that 
can increase and, fortunately, others that can decrease the risk of developing this type of 
diabetes [1].
One risk factor for T2DM is excessive weight gain.  Particularly individuals who 
are overweight and obese have increased rates of diabetes [8, 9].  Physical inactivity is 
also a risk factor for developing diabetes [10-12].  This could be a confounding factor 
since physical inactivity is also a cause for overweight and obesity.  Interestingly 
however, exercise and healthy diet, even in overweight individuals can decrease the risk 
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of developing diabetes, and this is independent of weight loss [13].  Poor diet can also 
lead to the development of diabetes, particularly diets high in fat and simple sugars [6].
Western diets, those high in saturated fats, refined carbohydrates and low in 
micronutrients, are particularly keen to the development of diabetes. This points to the 
fact that the specific macronutrients are important as to whether glucose intolerance will 
result, as certain fats are protective while others are not [14, 15]. Finally, tobacco 
smoking is a major risk factor for diabetes [16, 17].  Luckily, these risk factors are mostly 
modifiable, such that if one adopts healthy lifestyle changes including a healthy diet and 
consistent exercise and cessation of tobacco use, one can greatly reduce his/her risk of 
developing this chronic disease. 
There are additional risk factors that are not modifiable, those being male gender, 
certain ethnicities and age [18, 19].  Further, there is a rather large and unknown genetic 
component in T2DM etiology as concordance in identical twins is 90% although the 
genetic contribution is determined to be only 10% [20, 21].  Also, Americans from 
African and Hispanic descent develop the disease at higher rates than those of European 
and Asian descent [18].  Finally, there is evidence that diabetes risk can be affected by 
the intrauterine environment as determined by the maternal and developmental influences 
[22].  This idea that that the intrauterine environment can “program” the developing fetus 
and have long-term health consequences on offspring is called the Developmental 
Origins of Health and Disease (DOHaD) Hypothesis.  This hypothesis is fundamental to 
my dissertation and will be discussed fully in the upcoming sections.
1.1.2 Glucose homeostasis: Overview Upon ingestion of a meal, carbohydrates 
are broken down to their simplest sugars, monosacchrides.  This digestion begins with
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salivary and pancreatic amylase [23].  Villus enterocytes of the duodenum and jejunum 
produce hydrolases on their brush-border membrane which further digest carbohydrates 
into their monomeric sugars [23].  Absorption into enterocytes is carried out by sodium-
monosaccharide cotransporter, SGLT1. Sugars exit the cells at the basal lateral membrane 
via sodium-independent transporter, glucose transporter 2 (GLUT2) and enter blood 
stream via the portal vein [23].  Under normal conditions, the increased blood sugar then 
signals the pancreas to secrete insulin, an endocrine hormone whose function is to initiate 
glucose uptake from the blood stream into peripheral tissues to meet energy 
requirements.  Glucose uptake is mediated by glucose transporters (GLUTs), the main 
ones being GLUT1, GLUT2, GLUT3 and GLUT4 [6].  GLUT1 is ubiquitously expressed 
and is a moderate affinity, low capacity transporter of glucose, while GLUT2 is a low 
affinity, high capacity transporter expressed primarily in the intestine, kidneys, pancreas, 
and liver [6].  GLUT4 is an insulin-dependent glucose transporter whose expression 
facilitates glucose uptake in highly metabolic tissues of skeletal muscle and adipose [6].
When insulin binds its receptor, signal transduction results in the translocation of 
cytoplasmic GLUT4 to the cellular membrane where it transports glucose from the 
bloodstream into its respective tissue.  Type 2 diabetes is often caused by a defect in this 
insulin-dependent glucose uptake mechanism, particularly the insulin signal transduction.  
In addition to insulin’s role in peripheral glucose uptake, attenuated insulin signal 
transduction in the liver can lead to augmented hepatic glucose production and impaired 
adipose free fatty acid (FFA) uptake further elevating blood glucose levels and 
exacerbating glucose intolerance.  
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1.1.3 Insulin secretion and function Insulin is the primary mediator of glucose 
tolerance.  The -cells of the Islets of Langerhans take up glucose from the blood by way 
of GLUT2.  Once inside the -cell, glucose undergoes the normal process of glycolysis, 
providing substrates for mitochondrial respiration.  The increased intracellular ATP:AMP 
ratio begins a signaling cascade that results in depolarization of the cellular membrane, 
increased cytosolic calcium concentration and degranulation of stored insulin into the 
blood for systemic circulation [24].
There are insulin secretagogues that modulate insulin secretion, some being 
sympathetic and parasympathetic innervations, but of particular interest in normal 
glucose homeostasis, are incretin gut hormones, gastric inhibitory peptide (GIP) and 
glucagon-like peptide 1 (GLP-1) [25]. GIP and GLP-1 are secreted prandially by K and 
L cells of the intestine, respectively [26, 27].  These incretins potentiate glucose-
stimulated insulin secretion, but they are rapidly degraded by dipeptidyl peptidase 4 
(DPP4). Fifty percent of GLP-1 is degraded even before it reaches the portal vein, and an 
additional 40% is degraded in the liver [28-32].  In fact, the half-life of GLP-1 is only 60-
90 seconds.  GLP-1 also inhibits -cell apoptosis and promotes -cell survival and 
proliferation [33, 34].  In T2DM patients, GIP insulinotropic activity has been shown to 
be diminished by 54% and GLP-1 prandial release is attenuated [25, 35-38]. These 
incretins are being investigated for their potential use as anti-diabetic agents because their 
effects on augmenting insulin secretion are absent when blood sugar levels are low, 
thereby decreasing the risk of life-threatening hypoglycemia [39, 40]. Once insulin is 
secreted from the -cell into the systemic circulation, its actions in glucose regulation are 
mediated by insulin receptors on liver, skeletal muscle and adipose tissue. 
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The insulin receptor is a receptor tyrosine kinase.  Upon ligand binding, 
autophosphorylation of the subunit of the insulin receptor occurs [41-43].  Insulin 
receptor substrate (IRS) is recruited to the activated receptor and is itself phosphorylated 
[44].  Phosphorylated IRS then interacts with p85, the regulatory subunit of 
phosphotidylinositol 3 kinase (PI3K), targeting the enzyme to the plasma membrane [44,
45].  The product of this enzyme’s activity is phosphotidylinositol 3,4,5,-triphosphate 
(PIP3).  This molecule then recruits and activates other kinases including protein kinase C 
(PKC) protein kinase B (Akt) [46, 47].  Insulin signaling results in several events 
including translocation of GLUT4-containing intracellular vesicles to the plasma 
membrane in skeletal muscle and adipose tissue to facilitate glucose uptake [42].  In liver, 
insulin signaling deactivates glycogen synthase kinase 3 (GSK3) leading to the 
disinhibition of glycogen synthase, thereby increasing glycogen storage and quelling 
hepatic glucose production [48, 49].  Insulin resistance occurs when circulating insulin no 
longer elicits glucose normalizing responses.  As previously mentioned, as insulin 
insensitivity progresses, the
dysfunction and apoptosis and insulin deficiency [50].
1.1.4 Role of adipose, liver and muscle in glucose intolerance Insulin resistance 
can result from increased free fatty acid metabolism and ceramide production or also 
from inflammation [50-57].  Studies have shown that cytokines TNF- - -6
disrupt insulin signaling and lead to insulin resistance [58-63].  These cytokines in the 
context of diabetes are secreted primarily by adipose tissue, either the adipocyte itself or 
the infiltrating immune cells that accompany the tissue’s hypoxia [64].  Also, adipokines 
such as leptin and adiponectin modulate energy homeostasis and insulin activity, and 
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their levels are also disrupted in obesity [65-67].  This may explain the association often 
observed between obesity and diabetes.  Adipose tissue then is a major player in diabetes 
as it not only takes up free fatty acids and glucose, but also contributes to diabetes by 
modulation of its endocrine function [64, 68, 69]. Adipose tissue is responsible for less 
than 10% of whole body glucose uptake, yet genetic knockout of adipose tissue GLUT4 
causes hyperinsulinemia and hyperglycemia characterized by liver and skeletal muscle
insulin resistance, exemplifying its role in diabetes etiology despite its minor contribution 
to peripheral glucose uptake [70].
Similar to the pancreas, the liver expresses the insulin-independent glucose 
transporter GLUT2 [6]. Once inside the hepatocytes, glucose is phosphorylated by 
glucokinase (GCK), preventing its retrotransport back into the systemic circulation [71,
72]. Hepatic insulin signaling activates transcription of glucokinase [72, 73].  The 
phosphorylated glucose molecule then undergoes several fates such as glycolysis, stored 
as glycogen for later use, or can be used in the pentose phosphate pathway [6].
Moreover, in the fasted state when insulin levels are low, the liver undergoes 
glycogenolysis and gluconeogenesis to supply glucose to the periphery [74, 75].  Insulin 
signaling terminates these hepatic glucose production processes.  Consequently, hepatic 
insulin resistance causes decreased hepatic glucose flux due to decreased rate of 
intracellular glucose phosphorylation, thereby permitting GLUT2-mediated retrotransport 
of glucose back into the periphery [75].  The liver is also responsible for approximately 
70% of insulin degradation [76-78].  In diabetic subjects, hepatic insulin clearance is 
decreased anywhere from 20-65% [75, 79-81].  This presumably is protective against 
hyperglycemia by mediating increased circulating insulin to be used by skeletal muscle 
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and adipose tissue to facilitate glucose uptake. However, this decreased hepatic insulin 
clearance may precipitate peripheral insulin resistance and in turn produce a positive 
feedback loop of hyperglycemia and insulin resistance.  Further, it was observed that 
visceral fat is more detrimental to insulin sensitivity than subcutaneous fat [82-84].  This 
is interesting because glucoregulatory adipokines, cytokines and FFAs from visceral fat 
drain to the portal vein directly to the liver mediating impaired hepatic glucose 
homeostasis and insulin resistance [85].  Hepatic insulin resistance permits hepatic 
glucose production in the presence of elevated insulin which further increases blood 
sugar [86].  Together, the liver contributes to hyperglycemia both by decreasing glucose 
uptake and storage, but also by dysregulated glucose excursion.
Skeletal muscle is a major site of glucose disposal, accounting for upwards of 
90% of insulin-dependent peripheral blood glucose uptake, however approximately one 
third of postprandial glucose is taken up by the liver [7, 87-90].  Skeletal muscle 
intracellular transport is dose-dependently mediated by insulin.  Hyperinsulinemic 
euglycemic clamp studies in both lean and obese type 2 diabetics revealed a greater than
50% decrease in whole body glucose disposal [87].  This reduction in insulin-stimulated 
whole body glucose uptake was mirrored by a 50% increase in skeletal muscle EC50 for 
insulin-mediated glucose uptake [87].  Additionally, not only were the skeletal muscles of 
diabetic subjects resistant to insulin activity, a delay in the onset of insulin activity was 
also observed [87, 90].  Intramyocellular FFAs and impaired mitochondrial -oxidation 
are strongly associated with muscle insulin resistance, but it is difficult to establish a 
causal relationship between the two [90-92]. Nonetheless, the result is impaired insulin 
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signal transduction, impaired skeletal muscle metabolic flexibility, and consequently,
attenuated glucose uptake.  
1.2 Developmental Origins of Health and Disease
1.2.1 Thrifty Phenotype. Barker and Hales conducted epidemiological studies in 
the United Kingdom and observed that areas with the highest mortality rates were the 
same areas with the highest infant mortality rates several decades earlier [93-95]. Upon 
further investigation, it was discovered that not only did these geographical areas have 
higher rates of mortality but also higher rates of metabolic disease as well [22, 96-98].
They then put forth the Thrifty Phenotype Hypothesis which explains that developmental
perturbations result in low birth weight offspring who have an increased risk of 
developing cardiovascular and metabolic disease later in life.  Low birth weight is a 
phenotype resulting from intrauterine growth restriction which can have several causes 
including maternal undernutrition and uteroplacental insufficiency.  Initial studies 
investigated the role of maternal undernutrition on offspring body weight and aging-
associated sequelae.  In addition to low birth weight babies having increased risk of 
developing metabolic disease, large babies do as well.  Figure 1.2.1 diagrams the 
different intrauterine environments that precipitate metabolic disease that will be 
discussed in more detail.
1.2.2 Maternal undernutrition.  This hypothesis was evaluated in humans by 
investigating outcomes of offspring who were in utero during times of famine.  One of 
the first and most famous studies is that of the Dutch famine.  During the winter of 1944,
the Germans established a blockade of food to the Netherlands causing severe famine.  
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Investigations of offspring who were in utero during this period revealed that children 
were born with decreased placental and body weights although length and head 
circumference were relatively less affected [99]. It is thought that reduced fetal nutrient 
availability results in a brain-sparing effect [100, 101].  This describes vascular 
development and subsequent nutrient redistribution to more important organs such as the 
brain, heart and adrenal gland and the sequestration of nutrients away from visceral 
organs of the liver, and kidneys [102-104].  As a result, growth-restricted infants often 
have normal sized brains but underdeveloped visceral organs.  Often the kidneys of small 
infants have decreased nephron size and number, and moreover, the livers are smaller and 
hypoperfused [105-107].
Ravelli et al. showed upon 2 hr glucose tolerance test that offspring who were in 
utero during famine had increased glucose and insulin levels indicating impaired glucose 
homeostasis and insulin resistance compared to those conceived after or born before the 
famine [108]. It also appeared that those who were affected during the last trimester 
exhibited the most marked derangements.  Studies of Chinese Famine of 1959-1961 
revealed elevated risk of impaired glucose homeostasis of those adults who were in utero 
during famine [109, 110].  Those in utero during the most severe famine showed marked 
impairments over those whose nutrient restriction was less severe.  Additionally, the 
researchers found those adults who were exposed to nutrient restriction during famine but 
whose diets where rich later in life had the highest prevalence of glucose intolerance in 
adulthood [109, 110]. Developmentally malnourished offspring upon later life nutrient 
abundance demonstrated exacerbated glucose homeostatic maladaptation, illustrating 
continued nutrient response postpartum.  
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1.2.3 Catch-up growth There is now a theory that low birth weight offspring, 
when exposed to nutrient rich postnatal environment, display “catch-up” growth.  Catch-
up growth is a phenomenon by which underweight infants experience rapid postnatal 
growth eventually equaling and even surpassing the size of those born with normal birth 
weight. Low birth weight offspring that would later develop type 2 diabetes were taller, 
heavier, and had increased BMI by 7 years of age and during adolescents compared to 
normal weight offspring [111-113]. A study of low birth weight South African children 
revealed that those infants that underwent rapid weight gain during childhood exhibited 
the most profound impairments in glucose tolerance [114, 115].  This same association 
between catch-up growth and glucose intolerance was confirmed in Finnish children.  
Those infants who were small for gestational age and experienced the most rapid increase 
in BMI from 2 to 11 years of age were most likely to develop type 2 diabetes in 
adulthood [114, 116]. Ong et al conducted a literature review and found that rapid 
growth in infancy conferred a two to three fold increased risk of obesity with aging [117].
Not only is reduced birth weight and subsequent catch up growth associated with glucose 
intolerance, but reduced birth weight is also associated with obesity in older individuals.  
As mentioned in previous sections, the association between obesity and diabetes is well 
established; therefore it is possible that the increased risk of diabetes in small babies may 
be concomitant or secondary to the development of obesity. However the association 
with impaired glucose disposal is generally greater than with obesity, indicating that 
lifestyle probably plays more of a role in development of obesity than diabetes in the 
context of developmental programming.
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1.2.4 Animal models: general A wide variety of experimental techniques have 
been employed to corroborate the human data linking low birth weight to metabolic 
dysfunction in adults and also to elucidate the mechanisms involved.  Intrauterine growth 
restriction results in infants that are of decreased birth weight, or more precisely, small 
for their gestational age.  It is important to distinguish between the two as an infant may 
be small because of premature birth and the ramifications may be different depending 
upon prematurity or decreased fetal growth.  Experimental techniques use maternal low 
protein or low calorie diets, and uterine artery ligation to facilitate growth restriction.  
Each of the experimental animal models of growth restriction exhibit decreased birth 
weights compared to controls [118-122]. Although maternal undernutrition and 
uteroplacental insufficiency have reduced birth weight offspring, the responses may be 
quite different and consequently have varying mechanisms to disease progression [123].
1.2.5 Animal models of undernutrition Low protein (8% vs. 20%) isocaloric diets 
utilized later in gestation result in growth restricted offspring, demonstrated by decreased 
birth weights in rats despite comparable placental weights [121]. The brain sparing effect 
is also observed in this model.  Desai et al. showed offspring born to dams on low protein 
diet had the smallest changes in absolute brain and lung weights, while reductions in 
kidney, heart and thymus were proportional to the reduction in body weight, and the 
pancreas, spleen, liver and skeletal muscle had reduced weights even when taken as a 
proportion of body weight [124]. Regarding glucose homeostasis, both male and female 
offspring born to protein restricted dams display glucose intolerance and insulin 
resistance upon aging [125, 126].  Furthermore, pancreatic disturbances were observed 
including decreased -cell mass, diminished islet proliferation and vascularization, 
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decreased islet insulin levels, and attenuated glucose-stimulated insulin secretion [119-
122, 127-130]. The fetal pancreas also showed increased islet apoptosis [131]. Caloric 
restriction to at least 50% of ad libitum control animals also caused decreased birth 
weight and age related impairments in glucose tolerance [120].  This model also exhibits 
disturbances in the endocrine pancreas including decreased -cell mass and 
differentiation [120, 128]. Abrogated insulin signaling mediated by decreased and 
IRS-1 expression and increased serine phosphorylation of IRS-1 in skeletal muscle
indicates additional disruption in extrapancreatic tissues [132, 133].
As mentioned earlier, postnatal nutrition can further program the offspring toward 
age-associated metabolic disease.  Cross fostering studies in which offspring from 
malnourished dams were nursed to control dams, and vice-versa, support early postnatal 
nutrition as important factors in later life disease susceptibility. Growth-restricted 
offspring nursed to low protein diet dams have growth rates that are comparable to 
controls that persist as the offspring age, but the growth-restricted offspring weigh less 
than controls at every time point [124].  The greatest pre-weaning growth was observed 
in growth restricted pups that were fostered to control dams [124].  This intervention 
group actually weighed the same as controls by weaning in a different study [134, 135]
Tissue specific effects of maternal undernutrition include adaptations of the liver 
lobules which are larger in size yet fewer in number in growth-restricted animals [105].
Glucagon-stimulated glucose production was reduced, but insulin and glucagon together 
caused an initial increase in glucose output and delayed glucose output suppression [105,
136].  Skeletal muscle glucose uptake diminishes with age, owing at least in part to 
decreased expression of insulin signaling mediator PKC [133, 137]. The adipose tissue 
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from growth restricted animals resulted in age-dependent impairments in insulin-
stimulated glucose uptake and impaired inhibition of lipolysis resulting from attenuated 
activation of insulin-stimulated PI3K activation [138]. Taken together, the endocrine 
pancreas is disrupted with maternal undernutrition, but organs involved in glucose uptake 
are also disrupted and exhibit insulin resistance upon aging.
1.2.6 Uteroplacental insufficiency Uteroplacental insufficiency refers to 
incomplete attachment of the placenta to the uterus leading to diminished placenta 
vascularization and subsequent reduction of placental and fetal blood flow.  
Uteroplacental insufficiency thus results in placentas and fetuses that are hypoxic,
undernourished, and consequently growth restricted. It is the most common cause of 
intrauterine growth restriction in humans, especially in developed countries [139].
Uteroplacental insufficiency may have several causes including hypertension and 
maternal tobacco smoking [140].
Between 13 and 20% of American woman smoke cigarettes during pregnancy,
delivering one million infants exposed in utero to tobacco smoke [141].  Cigarette smoke 
contains approximately 4800 compounds including aryl hydrocarbon receptor (AhR)
agonists in the class of polycyclic aryl hydrocarbons such as benzo(a)pyrene and 
chlorinated dioxins and furans [141-144]. Maternal cigarette smoking is associated with 
a myriad of developmental defects including uteroplacental insufficiency resulting in 
reduced birth weight [145, 146]. It is also associated with increased risk of offspring 
obesity development [147-150].  An investigation of American Indian children up to 3 
years of age revealed the children whose mothers smoked at the initial prenatal visit were 
twice as likely to be in the 85th percentile of weight despite having reduced birth weight.  
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These 3 year old children born to mothers who smoked additionally had increased 
weight-to-length ratio z-scores due to increased adiposity as compared to those toddlers 
whose mothers were nonsmokers [147].  Data analysis from the 1958 British birth cohort 
showed smoking during pregnancy resulted in reduced birth weights compared to 
nonsmokers and that the odds ratio for obesity increased with age, and by 33 years of age 
both men and women born to smokers had statistically significant odds ratio for diabetes 
(1.56 and 1.41, respectively) [149]. Scientific data regarding maternal cigarette smoking 
and subsequent diabetes risk in the context of developmental programming is lacking.  
However, one study by Montgomery and Ekbom showed that maternal cigarette smoking 
not only increased the risk of obesity with aging, but showed a strong association 
between maternal smoking and later life diabetes prevalence by age 33 [150].  Moreover, 
offspring born to mothers who smoked at least 10 cigarettes per day during pregnancy 
were 4 times as likely to develop diabetes by age 33 than adults whose mothers did not 
smoke during pregnancy [150].
1.2.7 Animal models of uteroplacental insufficiency Sequelae of uteroplacental
insufficiency is studied experimentally by employing uterine artery ligation.  Uterine 
artery ligation growth restricts the developing fetus by reducing blood flow to the 
placenta [139, 151]. Consistent with uteroplacental insufficiency, the model exhibits
reduced -cell mass, impaired glucose homeostasis and decreased IGF-1 levels in growth 
restricted offspring born to uterine artery ligated dams [130, 152]. Rat pups born to 
ligated dams show global adiposity and insulin resistance as early as 10 weeks of age 
which is in stark contrast to the experimentally undernourished model whose offspring 
exhibit increased insulin sensitivity in early life and only exhibit insulin resistance and
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diabetes upon significant aging [120, 123, 125, 126, 130, 153]. Oxidative 
phosphorylation is impaired in the liver and skeletal muscle in offspring from ligated 
dams, and insulin-mediated GLUT4-dependent glucose transport in muscle is attenuated 
contributing to hyperglycemia [154, 155].  Pancreatic derangements may be mediated in 
part by aberrant pancreatic and duodenal homeobox 1 (Pdx1) expression via epigenetic 
modulations [118, 128, 156]. The Pdx1 gene plays pivotal roles in pancreatic 
development [118, 119]. Three month old offspring from uterine artery ligated dams 
displayed reductions in Pdx1 gene expression which was concomitant with an 80% 
reduction in -cell mass. Interestingly, GLP-1 receptor agonist, Exendin-4, administered 
at birth restored Pdx1 mRNA levels and ultimately -cell function [157, 158]. Exendin-4
further reduced hepatic oxidative stress and insulin resistance [157, 159].
1.2.8 Developmental Programming associated with high birth weight
Developmental programming of adult disease is not limited to those growth restricted 
offspring; high birth weight offspring, too, have increased risk of later life metabolic 
diseases [160-163].  There is a loss of maternal insulin sensitivity in late gestation in 
normal pregnancies so as to increase insulin and nutrient availability for the developing 
fetus, but this can lead to gestational diabetes when this insulin resistance becomes 
pathologic.  The Pima Indian population have increased incidence of diabetes [164-166].
Studies on this unique population revealed that both low birth weight and high birth 
weight babies have increased risk of developing type 2 diabetes suggesting a U-shaped 
relationship [167].  Pima Indian females whose mothers had gestational diabetes were 
also more likely to develop diabetes [165].  Not only does diabetes lead to high birth 
weight and metabolically perturbed offspring, but maternal obesity does as well.  When a 
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high fat obesogenic diet was given before mating, during gestation, and lactation, the 
offspring were hyperphagic and had increased adiposity and insulin resistance [168].
Also, offspring of obese mothers have developmentally programmed nonalcoholic fatty 
liver disease which can have additional metabolic sequelae including insulin resistance
[169]. Mestan et al showed correlations of maternal BMI and diabetes status (Type 2 or 
gestational) were both positively correlated with large-for-gestational age offspring 
phenotype, OR 2.64, 95% CI 1.31-6.20 and OR 5.58, 95% CI 2.06-15.13, respectively
[170].  Also the adipose tissue secreted cytokine RANTES in cord blood was found to be 
correlated with large-for-gestational age and ponderal index in offspring [170]. Harder et 
al conducted a meta-analysis of 14 studies investigating the association between birth 
weight and adult Type 2 diabetes incidence and confirmed the U-shaped association
[171].
1.2.9 Conclusion Perturbations in the plastic periods of development during 
gestation and infancy can have long lasting physiological effects which predispose one to 
increased metabolic disease susceptibility later in life.  There are varying causes of 
reduced birth weight and similarly different yet converging paths to disease progression.  
Fortunately, excellent experimental models of growth restriction and developmental 
programming are available to help elucidate the mechanisms behind disease progression 
in the two most prevalent causes on reduced birth weight.  Uteroplacental insufficiency 
can result from exposure to environmental toxins such as those found in cigarette smoke 
and predispose offspring from maternal smokers to metabolic disorders later in life.  
Similar to chemicals in cigarette smoke, polychlorinated biphenyls (PCBs) are also 
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environmental toxins that activate the AhR, suggesting that they may also diminish
intrauterine growth and precipitate postnatal metabolic derangements.
1.3 Polychlorinated biphenyls
1.3.1 History of polychlorinated biphenyls PCBs are a class of persistent 
organochlorine pollutants that partition with lipids and biomagnify in the food chain 
resulting in dietary exposure [172-174].  PCBs are dielectric molecules whose heat 
resistant properties afforded many industrial uses including in electrical insulating fluids 
and heat exchange fluids.  They were used in electrical equipment such as transformers 
and capacitors, fluorescent light ballasts, plastics, adhesives, paints, varnishes, and paper 
[174, 175].  PCBs were manufactured in the United States under the trade name Aroclor.  
In the 1970’s two accidental exposures in Southeast Asia revealed some potential health 
hazards associated with dietary PCB exposure.  These two incidents are the Yusho and 
Yu-Cheng incidents of Japan and Taiwan, respectively, in which populations were 
exposed to PCB via contaminated rice bran cooking oil [176-179].  Exposed subjects 
presented with chloracne, hyperpigmentation, ocular lesions, neurological symptoms 
including numbness, nausea and headaches, and digestive indications including vomiting 
and diarrhea [180].  Consequently, the US Environmental Protection Agency (EPA) 
banned production of PCBs in 1976 although use of the compounds was still permitted.  
Investigations of PCB-associated health hazards in Western and European countries 
confirm those of the Yusho and Yu-Cheng incidents, and additional health hazards 
associated with PCB exposure have been observed including cancer, hypertension, 
immune and thyroid dysfunction, asthma, obesity, diabetes and low birth weight [181-
183]. Over one billion pounds of PCBs were produced in the United States in the 50 
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years of their production, and PCBs, particularly those with more chlorine substitutions, 
resist biodegradation and therefore persist in the environment [173].  Although their 
production has long ceased, currently over 450 million pounds have contaminated our 
environment and PCBs are found in over 29% of hazardous waste sites in America and 
have thus been categorized as ubiquitous environmental pollutants [173, 175, 184].
1.3.2 PCB Exposure PCBs enter the environment by improper disposal of PCB 
waste and leakage of PCB containing fluids from electrical equipment.  They then
partition to the nonpolar components of the environment, particularly soil and sediment,
due to their hydrophobicity.  When PCBs are volatilized they become airborne leading to 
their detection in the atmosphere [185], and these characteristics give rise to their ability 
to bioaccumulate in food chain [181].  Human exposure can be occupational for those 
whose work involves PCB-containing materials, but for the majority of Americans, PCB 
exposure is dietary coming primarily from animal based foods such as milk, beef and fish
[174]. Greatest dietary exposure comes from beef consumption although fatty fish such
as farm raised salmon have higher PCB concentrations on average [172, 174].  This 
disparity is owed the large proportion of beef in the Western diet compared to fish.  
Because fish have far greater levels of PCBs, some studies use sport fish consumption as 
an estimate of exposure levels above background [186, 187].
PCBs have been detected in lipid rich tissues including adipose tissue, central 
nervous system, liver, serum, placenta, cord blood and breast milk [186, 188, 189].  The 
discovery of PCBs in placenta, cord blood and breast milk indicate exposure to these 
pollutants as early as the time of embryonic implantation and throughout gestation, 
lactation and the entire life course after weaning [188]. Owing to cessation of production 
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and successful remediation procedures, environmental and body burdens of PCBs are 
declining [190-192].  Fetal development is quite plastic and responsive to subtle changes 
in its intrauterine and the early postnatal environment, as discussed regarding fetal 
programming of metabolic disease [193, 194].  Also, several of the PCB-associated 
health hazards were shown to have inverted U-shaped relationships suggesting that low 
level exposures associated with declining environmental levels and body burdens may 
actually be more detrimental than expected [195-198].
PCB exposure in the general population has been shown to be associated with low 
birth weight in several epidemiological studies [182, 199, 200].  It then stands that in the 
context of DOHaD, perinatal PCB exposure resulting in low birth weight may lead to 
programming of metabolic diseases such as obesity and diabetes.  Studies investigating 
the association between PCBs and metabolic disease are done based upon postnatal PCB 
exposure [183, 201-205].  Few studies have looked at perinatal exposure and subsequent 
development of obesity with most prospective studies ending prior to adolescents and 
having inconsistent results [206, 207]. Epidemiological studies investigating dietary 
exposure and body burdens in adulthood show clear associations although causal 
relationships are difficult to ascertain [208-210]. Regarding diabetes, even fewer studies 
have investigated the association between early life pollutant exposure and diabetes risk 
later in life.  It does seem clear however that there is a correlation between diabetes risk 
and PCB exposure as indicated by studies showing lack of association between obesity 
and diabetes in subjects with lowest levels of PCBs and diabetes incidence increasing 
with increasing plasma PCB concentrations [198, 204, 211].  Also, associations between 
PCB exposure and diabetes are found predominantly in females, demonstrating sex-
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specific effects of PCBs [212]. The contribution of PCBs to diabetes etiology is under-
investigated.  Data regarding mechanisms of hyperglycemia in PCB-associated diabetes 
are inconclusive. Some studies suggest the effect of PCBs on diabetes is not mediated 
through insulin resistance but rather attenuated insulin secretion as evidenced by a
negative association between PCBs and homeostatic model assessment (HOMA)- (an 
estimate of -cell function), but no association with HOMA-IR (measure of insulin 
resistance based upon fasting glucose and insulin levels) [211-213]. Some studies 
however, show positive associations with PCBs and insulin resistance [204]. Animal and 
in vitro studies demonstrate PCB-induced insulin resistance mediated predominately by 
adipose tissue [214, 215]. Although the association between PCB exposure and impaired 
glucose homeostasis is rather evident, the mechanism remains unknown, as do the effects 
of perinatal PCB exposure on glucose tolerance.
1.3.3 PCBs and AhR PCBs are composed chemically of two covalently bonded 
benzene rings with at least one chlorine molecule substitution.  Given that there are 10 
different locations for chlorines to bind, there are 209 different combinations of chlorine 
number and position; each different combination is called a congener [216].  There are 
some congeners that are non-ortho or mono-ortho substituted that have coplanar 
conformations while those having multiple ortho substituted chlorines display steric 
hindrance and are referred to as non-coplanar.  Coplanar PCBs bind AhR whose 
canonical ligand is 2, 3, 7, 8-tetrachlorodibenzo-p-dioxin, also known as TCDD or simply 
dioxin [216].  For this reason, coplanar PCBs are often referred to as dioxin-like PCBs.  
The AhR is a ligand-activated DNA-binding transcription factor [217].  The receptor 
resides in the cytosol interacting with heat shock protein (HSP) 90, prostaglandin E 
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synthase 3 (p23), AhR interacting protein (AIP) [143, 218-221].  Upon ligand binding, a
conformational change uncovers the receptor’s nuclear localization signal causing its 
nuclear translocation [222].  Once in the nucleus, the receptor dimerizes with the aryl
hydrocarbon nuclear receptor (ARNT) at which time it interacts with xenobiotic response 
elements and regulates gene transcription [223, 224].  AhR facilitates transcription of 
detoxifying enzymes such as cytochrome P450s (Cyp) 1a1, Cyp1b1 and phase II 
enzymes, glucuronosyltransferases (UGTs) and glutathione-s-transferases (GSTs) [143].
Moreover, the receptor can interact with other transcription factors including nuclear 
factor (erythroid-derived 2)-like 2 (Nrf2), ER and RelA subunit of 
nuclear factor kappa-light-chain-enhancer of activated B cells (Nf- b), thereby 
modulating their activities [225-230].  The detoxification process produces free radicals 
which can cause oxidative stress and disruption or activation of redox responsive 
signaling pathways [231].  These cellular AhR-dependent redox responses can contribute 
to a myriad of pathological phenotypes leading to the aforementioned PCB-associated 
diseases [232]. In fact, epidemiological studies find more positive correlations between 
coplanar PCB exposure than with non-coplanar PCBs [212, 233-237].
1.4 Scope of Dissertation
1.4.1 Aims of dissertation The main purpose of this dissertation was to determine 
whether PCB exposure during the critical windows of development, during gestation and 
lactation, has an adverse effect on offspring body composition and glucose homeostasis.  
Finally, I investigated changes in maternal hepatic gene expression during pregnancy and 
in fetal and offspring livers perinatally exposed to PCB.  These studies elucidate a role of 
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early life environmental contaminant exposure in the subsequent development of obesity 
and diabetes.
1.4.2 Rational Epidemiological studies support an association between PCB 
exposure metabolic disease.  In support of the human studies, Baker et al, have recently 
shown that direct exposure to coplanar PCBs cause adipose tissue inflammation and 
insulin resistance leading to impaired glucose tolerance in male mice [214].  It is clear 
however, that PCB exposure begins in utero and exposure this early in development can 
have detrimental effects such as increased rates of malformations.  This perturbation of 
fetal development is evidenced also by decreased birth weights of offspring born to 
mothers with increased exposure to PCBs.  In the context of the DOHaD then, it is 
reasonable to assume that these offspring will present with metabolic maladies of obesity 
and diabetes.  Studies investigating prenatal PCB exposure on offspring body 
composition reveal sex specific increases in adiposity and reduced lean mass in female 
children 6.5 years of age, with boys of the same age being symmetrically smaller [238,
239]. At puberty, prenatal PCB exposure was associated with increased BMI in 
Caucasian adolescents [238].  Further, the observed increase in body weight with prenatal 
exposure holds true even when adjusted for postnatal exposure [239]. In vitro studies 
support a role of PCB exposure in this phenotype as these pollutants inhibit skeletal 
muscle differentiation and augment adipocyte differentiation [240, 241]. However, one
study investigated the effects of estimated prenatal PCB exposure on adult body weight
in females only, and it found no association between body weight and prenatal PCB
exposure [242].
 
24 
 
Epidemiological evidence shows positive associations between PCB body burden 
and perturbed glucose homeostasis, but the contribution of perinatal PCB exposure to this 
disease phenotype has not been investigated. Langer et al, in their investigation 
environmental pollution with impaired fasting glucose and thyroid dysfunction, 
concluded that there is likely transgenerational transmission of these phenotypes 
engendered by perinatal PCB and other pollutant exposure of the parent generation [187].
Despite the lack of evidence for a causal relationship between PCB exposure and 
diabetes, the DOHaD provides rationale for PCB-induced disruption of glucose tolerance 
in adults as sequelae to their disrupted fetal development.  Nonetheless, further 
investigation into the role of perinatal pollutant exposure on offspring glucose tolerance 
is clearly warranted. Finally, the livers primary function is macronutrient homeostasis 
and xenobiotic detoxification.  The effects of xenobiotic detoxification on hepatic gene 
expression has been studied, but not during pregnancy and fetal development, and not 
using PCBs. Moreover, a role of AhR in liver organogenesis has been identified, 
indicating temporal and spatial opportunity for AhR agonists to exert effects during 
hepatic development and maturation that may have long-term consequences.  
1.4.3 Hypothesis and specific aims Hypothesis: Maternal coplanar PCB exposure 
during pregnancy and nursing will result in reduced birth weight offspring that will 
develop obesity and glucose intolerance with aging. Figure 1.4.1 diagrams the overall 
hypothesis and experimental approach to the dissertation.  Aim 1: To test the hypothesis 
that perinatal PCB exposure will cause reduced birth weight and disease-associated 
modulation of body composition in aged offspring.  Aim 2: To test the hypothesis that 
perinatal PCB exposure will impair glucose tolerance.  Aim 3: To investigate alterations 
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in liver gene expression pattern upon PCB exposure during pregnancy and fetal 
development.
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Maternal Undernutrition
•Famine
•Eating disorders
Fetal  Overnurtition
•Western diet
•Maternal diabetes
Placental Insufficiency
• Hypertension
•Cigarette smokingCauses
Animal 
Model
Maternal low protein or 
low calorie diets
Uterine artery ligation Maternal high fat or high 
calorie diets
•Large functional placenta
•Fetal overgrowth due to 
increased building blocks 
and insulin
•Normal placental function
•IUGR due to lack of 
building blocks
•Small and dysfunctional 
placenta
•IUGR due to decreased 
blood flow
In Utero
Outcome Increased Risk of Obesity and Diabetes with Ageing
Figure 1.2.1 Overview of developmental origins of metabolic disease.  Maternal 
undernutrition and placental insufficiency both cause intrauterine growth restriction 
(IUGR) although by different mechanism.  Fetal overnutrition can result in unusually 
large fetuses.  Interestingly, however, these various fetal milieus precipitate a convergent 
phenotype of increased obesity and diabetes risk.  Fortunately, experimental animal 
models have been developed to elucidate the mechanisms involved.
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Figure 1.4.1 Specific Aims Diagram.  Female CD-1 mice were exposed biweekly to 
safflower oil vehicle or PCB 126 via oral gavage such that mice exposure occurred near 
the time of conception, and once also during gestation and lactation.  One cohort of mice 
was allowed to deliver their litters and nurse.  These offspring were evaluated for body 
composition and glucose tolerance in Aims 1 and 2, respectively.  A separate cohort was
sacrificed at embryonic day 18 (E18) and pups and placentas were weighed to determine 
in utero developmental blight.  Absolute messenger RNA quantitation of livers from 
fetuses, dams, and non-impregnated females were performed using NanoString nCounter 
Technology in Aim 3.
Copyright © Cetewayo Saif Rashid 2013
 
28 
 
CHAPTER 2
PERINATAL POLYCHLORINATED BIPHENYL 126 EXPOSURE ALTERS 
OFFSPRING BODY COMPOSITION 
2.1 Abstract 
Polychlorinated biphenyls (PCBs) are ubiquitous environmental contaminants whose 
exposure levels are associated with various health hazards.  We hypothesized that in 
utero and lactational exposure to PCBs can cause changes in body composition and 
obesity in a mouse model.  Pregnant mice were exposed biweekly to increasing 
concentrations of PCB 126 via oral gavage.  Maternal PCB exposure did not result in 
heavier offspring, however, dose-dependent and sex specific changes in body 
composition were observed.  Female offspring displayed the most susceptibility to PCB-
induced alterations in body composition, having less percent lean body mass and 
increased adiposity compared to females born to control dams, and these effects were 
largely dose-dependent.  In contrast to females, and independent of the exposure level of 
PCB 126, male offspring had reduced lean body mass but no change in fat mass 
compared to males born to control dams.  In conclusion, perinatal PCB 126 exposure did 
not affect body weight, but rather modulated body composition in a dose-dependent and 
gender-specific manner.
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2.2 Introduction
Polychlorinated biphenyls (PCBs) were produced in the United States (US) until their 
ban in 1976 upon realization of their many hazards to human health [174].  Although 
production of PCBs has long ceased, environmental contamination remains, and PCBs 
are found in over 29% of hazardous waste sites in the US [174].  Primary sources of PCB 
exposure for the general population include contact with ground water or contaminated 
soil due to inappropriate disposal of materials containing PCBs, food contamination from 
food storage in silos with PCB-coated interiors, and consumption of fish from 
contaminated waterways [174]. Additionally, PCBs resist biodegradation, are lipophilic, 
and consequently bioaccumulate in the environment and in the food chain, thus exposing 
millions of Americans to these toxic compounds [173].
PCBs are ubiquitous and persistent environmental pollutants whose presence in utero
perturbs fetal development.  The developmental origins of health and disease hypothesis, 
derived from the thrifty phenotype hypothesis put forth by Barker and Hales in 1992, 
postulates that low birth weight offspring can result from insufficient nutrition in the 
intrauterine environment, leading to metabolic and other health derangements later in life 
[22, 243-247].  Animal models of low birth weight employing uterine artery ligation and 
protein or calorie restriction all show catch up growth and subsequent obesity with aging.
In fact, maternal serum PCB levels in humans negatively correlate with infant birth 
weight and weight for gestational age [182, 199, 200, 248-251].  A meta-analysis 
comparing prenatal PCB exposure and birth weight effects across 12 European birth 
cohorts found a significant negative correlation between cord blood PCB levels and birth 
weight [182].  Other studies confirmed that low-level PCB exposure during the perinatal 
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period can significantly affect fetal growth and birth weight [199, 248-253].  In contrast, 
other studies found minimal or no correlation between perinatal PCBs and birth weight 
[254, 255].
Prospective studies investigating the effects of PCB exposure on body weight are 
incongruent, to say the least.  Tang-Peronard et al. review of the literature in 2011 cited 
eight prospective studies looking at the effects of prenatal PCB exposure on body weight; 
3 found positive associations with body weight, while another 3 found negative 
associations  and the remaining 2 found no significant relationship between the two 
variables [200, 206, 208, 238, 242, 250, 256-258].  Further, non-monotonic dose-
dependent relationships were observed [208].  The 2 prospective studies found positive 
associations with low PCB exposure (<1.0 ng/mg serum lipid) and body weight while 
high exposure (>4 ng/mg serum lipid) was correlated with decreased body weight [202,
[200, 256, 257, 259].  Maternal serum levels between these amounts were divergent with 
some showing positive, negative and nonsignificant associations [206, 238, 242, 250,
258]. These effects were divergent regarding gender such that prenatal PCB exposure 
predominantly affected females in the nonmonotonic manner, while the male offspring 
were unaffected [208, 239].  These prospective studies, however, are limited in that only 
Karmaus et al investigated maternal PCB exposure on adult offspring which were of the 
female sex, and they found no association with maternal PCB exposure and BMI [242].
This is in contrast to cross sectional and case control studies that find significant 
associations with obesity and serum concentrations of PCBs in males [121, 208, 209,
260-263].  The lack of effect of prenatal PCB exposure in young males, but not females, 
but with effects observed in cross sectional studies is intriguing.  Cross sectional studies 
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cannot determine causality, therefore the possibility of PCB induced developmental 
programming of obesity in males cannot be ruled out.  Nonetheless, these studies indicate 
sex specific effects of PCB exposure on obesity.
Experimental studies utilizing animal models and in vitro techniques further 
demonstrate a role of PCB in adipose tissue development.  Specifically, Arsenescu et al 
showed that dioxin-like PCB 77 or TCDD itself at low doses increased adipocyte 
differentiation in 3T3L1 preadipocytes whereas higher concentrations inhibited adipocyte 
differentiation.  Additionally, in wildtype but not aryl hydrocarbon deficient mice, direct 
exposure of PCB 77 increased weight body weight mice [241].  These data provide a 
mechanism by which developmental exposure to dioxin-like pollutants can affect 
adipocyte differentiation in nonmonotonic dose-dependent manners observed in human 
studies.
Moreover, the decreased body weight observed primarily in females upon higher 
exposure levels can be concomitant with hypotonia and diminished physical activity in 
preschool aged children, but these effects are short-lived as they are not observed into 
puberty [258, 264]. These effects were thought to be due to lactational exposure rather 
than exposure in utero suggesting that heightened perinatal exposure, due in part to breast 
milk contamination, decreases body weight [258, 264]. The effect of perinatal PCB 
exposure on offspring lean mass is not well established, therefore using only BMI and 
body weight as marker of obesity is unavailing because they do not take into account the 
possible effects of PCB exposure on lean mass.  Coletti et al found that Aroclor mixtures 
of PCBs dose-dependently diminish skeletal muscle differentiation in primary fetal 
myoblasts and in a myogenic cell line without affecting viability or proliferation, 
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supporting a role of PCB exposure on the disruption of skeletal muscle development in 
utero [240].
Evidence suggests that exposure to environmental pollutants can contribute to the 
pathology of obesity, and recent human studies support our hypothesis that perinatal 
exposure to PCBs is associated with overweight offspring [182, 239].  Thus, the purpose 
of this study was to investigate gender-specific differences in body composition of both 
young and aged offspring born to PCB-exposed dams.
2.3 Materials and Methods
2.3.1 Animals and diets: At 2 months of age, female ICR mice were bred and 
subsequently produced one litter at Taconic prior to their purchase and shipment to the 
University of Kentucky at roughly 4 months of age.  The following studies were carried 
out at the University of Kentucky according to an approved Institutional Animal Care and 
Use Committee protocol.  Females were housed 4 mice per cage for a 2 week acclimation 
period prior to mating.  Female mice were fed a semi-purified low fat diet containing 
10% kcal from fat (Research Diets D12450B) ad libitum for the duration of the study.  
Male ICR sires (Taconic) were fed standard chow (Teklad Global 18% Protein Rodent 
Diet #2018) during a 7 day acclimation period then mated to dams, 1 sire per 2 dams.  In 
order to equilibrate nutrient availability, litters were culled to 6 pups on postnatal day 3.
Pups from litters with more than 6 pups that were born on the same day were cross-
fostered to dams nursing less than 6 pups.  Body weight and maternal food intake were 
monitored weekly throughout weaning.  Pups were weaned on postnatal day (PND) 21 
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onto standard chow, and male and female offspring were housed 3 and 5 mice per cage, 
respectively. 
2.3.2 PCB Exposure: 3,3’,4,4’,5-pentachlorobiphenyl (PCB 126) was purchased from 
AccuStandard (C-126N New Haven, CT).  PCB 126 was dissolved in tocopherol stripped 
safflower oil (Dyets # 403952 Bethlehem, PA).  Female mice were orally gavaged with 0, 
0.5 or 1.0 μmole of PCB 126 per kg body weight at a frequency of once per 14 days.  The 
frequency was such that the dams were exposed to PCB 48 hours prior to mating, once 
during gestation, and once during lactation (Figure 1).  
2.3.3 Body composition: At 7 weeks, 6 months and 9 months of age, nuclear magnetic 
resonance (EchoMRI; EchoMedical Systems; Houston, TX) was employed to quantify fat 
mass and lean body mass in both female and male offspring born to vehicle or PCB 
exposed dams.  Although many tissues contribute to the lean mass output, there are 
undetectable components such as bone mineral content, hair, and claws which contribute 
to void mass.  Body composition measurements in Tables 2 - 7 include data from only 
one female and one male offspring per litter, respectively. Body weight was measured 
just prior to body composition analysis.
2.3.4 Statistics: Overall differences in maternal body weight were determined by 
repeated measures ANOVA using IBM SPSS statistics 20 software. One-way ANOVA 
was used to make comparisons between groups for the remaining comparisons in Tables 
1-3.  Fisher LSD Method was used for post hoc comparisons.  Upon the event of a failed 
Shapiro-Wilk normality test, data were transformed using natural log.  Kruskal-Wallis 
ANOVA on Ranks was used when the data failed the equal variance test or failed 
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normality following transformation.  These analyses were completed using SigmaPlot 
12.0 software.
2.4 Results
2.4.1 Maternal effects of biweekly PCB 126 exposure and pup body weight: Figure 1A 
illustrates the perinatal exposure model used in the current study. Exposure at 
concentrations of 0.5 and 1 μmole PCB per kg body weight did not affect pregnancy rate 
(Table 2.1) or maternal body weight (Figure 2.1B) when compared to vehicle controls.  
In order to promote successful rearing, litters were not disturbed until postnatal day 3, at 
which time pups per litter were enumerated.  The 1 μmole/kg dose led to significantly 
decreased litter size compared to controls.  There was no significant difference in pup 
body weight on PND 3 although there was a trend toward decreased body weights in 
male offspring maternally exposed to PCB 126 compared to those from control dams at 
postnatal day 21 (p=0.083) (Table 2.1).  
2.4.2 Body composition analysis: At 7 weeks, 6 months and 9 months of age, body 
composition analyses were conducted using EchoMRI, and the data are presented in 
Tables 2.2 – 2.7.  Perinatal PCB exposure resulted in gender specific differences in body 
composition.  Females born to PCB exposed dams had similar body weights, yet 
displayed significantly increased adiposity compared to females born to vehicle treated 
dams.  Females perinatally exposed to 0.5 μmole/kg and 1 μmole/kg PCB 126 showed a 
dose-dependent 8.2% and 11.5% increase in percent body fat compared to females born 
to control dams (p=0.044 and p<0.001, respectively).  The largest effect was seen in the 
high exposure group as these offspring additionally displayed significantly elevated fat 
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mass and a nearly 4% reduction in percent lean body mass (p=0.004 and p=0.005, 
respectively). Despite a lack of difference in body weight upon perinatal PCB 126
exposure, there were significant alterations in body composition at this early time point.
While prospective epidemiological studies show an increase in body weight as 
representative of increased fatness in female offspring, we too demonstrated an increase 
in fatness.  The decrease in lean mass contribute to comparable body weights despite 
increased grams of fat mass and increased % fat mass in these females. With aging, these 
PCB-induced effects are attenuated such that body composition is comparable in females 
perinatally exposed to PCB and control animals at 6 and 9 months of age, Tables 2.4 and 
2.6, respectively.  
For male offspring at 7 weeks of age, there was no significant effect of perinatal PCB 
exposure on body weight (p=0.368).  In contrast to that which was observed in females, 
male offspring born to PCB exposed dams showed no difference in adiposity taken as 
either weight of fat mass or when expressed as a percentage of body weight (p=0.876 and 
p=0.536, respectively).  There was, however, a significant reduction in grams of lean 
mass between the groups; specifically, males perinatally exposed to 0.5 μmole/kg and 1 
μmole/kg PCB 126 showed significant reductions in lean mass (8.3% and 9.9%, 
respectively).  However, there was no significant difference in percent lean mass 
(p=0.268). Perinatally exposed males at 6 months of age had a dose-dependent decrease 
in body weight compared to controls, most of which is attributed to reductions in grams 
of lean mass of PCB-exposed mice (Table 2.5).  Specifically, these males born to dams 
administered 0.5 μmole/kg PCB 126 displayed 10.5 and 10.4 percent reductions in body 
weight and lean mass, respectively, while males born to dams given 1 μmole/kg PCB 126 
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exhibited 13.1 and 15.1 percent reductions in body weight and lean mass, respectively.  
This diminished lean mass accounted for 63 and 74% of the reduced lean mass in the 0.5 
and 1 μmole/kg exposed males respectively.  These trends persisted with further aging 
such that at 9 months of age there was again dose-dependent reductions in lean mass in 
PCB exposed males although the body weight difference was no longer statistically 
significant (p=0.058) (Table 2.7).  The reduction in lean mass is dose-dependently, 11.2% 
and 17% for the two PCB exposed groups, respectively.  Interestingly, the 0.5 μmole/kg 
decrease in lean mass is actually greater than the reduction in body weight for that group, 
an effect made possible by a slight increase in fat mass.  
2.5 Discussion
The current study focused on the effects of perinatal PCB exposure on gender-
specific body composition changes in the offspring.  Because many studied causes of low 
birth weight are due to intrauterine growth restriction resulting from maternal 
undernutrition, it is important to note that maternal body weight was not affected by PCB 
exposure [22, 112, 265, 266].  It is uncertain whether or not the congener dosing and 
frequency used in this experiment caused low birth weight because initial pup weights 
were not measured until PND 3 instead of PND 0 so as to promote successful rearing. 
Nonetheless, there was no difference in body weight between pups born to control or 
PCB exposed dams at the first measurement of offspring body weight at PND 3.  In fact, 
pup body weights were comparable throughout weaning.  When mice were sexed at 
postnatal day 14, there was also no difference in body weight between treatment groups 
within each gender.  In the event that low birth weight had occurred, it is unlikely that 
catch up growth would have occurred 3 days post-partum [267, 268]. Further, in Aim 3 
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we measured fetal weights at day 18 of gestation in vehicle and PCB exposed dams and 
no significant differences in fetal weights were noted.
Possible toxicity of our dosing regimen was evidenced by the reduced litter size in the 
1 μmole/kg PCB 126 dose compared to control.  The observed reduction in litter size is a 
likely consequence of poor rearing because unpublished data from our laboratory 
revealed no differences in fetal number at embryonic day 18 when dams were 
administered 1 μmole/kg PCB 126 as in the current exposure model (see Aim 3).  Studies 
in humans have shown conflicting effects of maternal PCB exposure on fecundity, and 
specifically time to pregnancy [269-274].
In the present study, at 7 weeks of age, there was still no effect of perinatal PCB 
exposure on offspring body weight in these mice.  Hertz-Picciotto et al. showed that in 
humans, in utero PCB exposure of males was associated with low birth weight and body 
weight for gestational age in boys, while in girls, in utero exposure was associated with 
shorter gestation [200]. In the same study, at five years of age, prenatal PCB exposure 
was associated with increased growth in girls but not boys [200].  Additionally, a recent 
prospective study conducted in humans revealed a significant positive correlation 
between cord blood concentrations of PCBs and overweight in females 6.5 years of age 
[239].  The males in that study did not exhibit such an association, although there was a 
trend toward a negative correlation between moderate prenatal PCB exposure and 
overweight.  Our current experiment shows similar trends (Tables 2.2 and 2.3), such that 
perhaps with an increased sample size, we too would have observed statistically 
significant dose and gender-specific effects of maternal PCB exposure on body weight.  
Interestingly, when Valvi et al. adjusted for birth weight, the association between 
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overweight and PCBs strengthened, and the findings still held true even when only 
normal birth weight offspring were included, suggesting that prenatal PCB exposure in 
the absence of low birth weight may still contribute to the overweight phenotype [239].
Although it was assumed that increased weight at 6.5 years of age was caused by 
increased adiposity, confirmation was not provided [239].
In the current experiment, body composition analyses showed female offspring born 
to PCB exposed dams had increased adiposity as well as reduced lean body mass 
compared to offspring from vehicle treated dams despite comparable body weights.  The 
observed adiposity is consistent with published data in mice which demonstrated 
coplanar PCB 77 augmented body weight gain, adiposity, and adipocyte differentiation 
[241].  There are previous reports in humans of PCB levels correlating with decreased 
muscle tone in females and from these studies, it appears evident hypotonia occurs 
preferentially in females [275-277]. Also, there is evidence that while in utero exposure 
best correlates with later life neurocognitive impairments, it is lactational exposure that 
best associates with hypotonia [258, 275, 276].  In the present study, male offspring 
displayed no such increased adiposity.  In contrast to females, male offspring born to 
dams exposed to 1 μmole PCB 126 /kg body weight had decreased lean body mass 
compared to control males (Table 2.3).
It is interesting that with aging, the effects of PCB exposure on female offspring are
attenuated.  This could be indicative of a direct exposure effect in the females because 
without additional dietary exposure to PCBs the body burden would decrease mirroring 
the decreased difference in body composition observed between PCB exposed females 
and controls.  The body composition effects in the male offspring persisted.  Intriguingly, 
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there was no alteration in adiposity demonstrated at any time during the course of the 
study which is in agreement with prospective studies [200, 206, 208, 238, 239, 250, 258].
The majority of cross sectional studies found an increase in body weight in males [121,
260, 262].  The divergence between these cross-sectional studies and the present one may 
be attributed to a myriad of factors including timing and duration of exposure, nutritional 
status and of course species. 
Timing of maternal exposure may be important in PCB-induced abnormal 
development, and consequently future studies will include cross-fostering of pups born to 
PCB-treated dams with those of vehicle-treated dams to further clarify compositional 
changes induced by exposure to PCB.  Cross-fostering will allow us to establish whether 
PCB exposure in utero or during lactation precipitates these aberrant changes in body 
composition. If lactational exposure is deemed most detrimental, then perhaps steps could 
be taken to minimize lactational exposure such as formula feeding.
Results from the presented experiment are similar to findings in humans, thus 
supporting current and future use of this exposure model to assess effects of maternal 
PCB exposure on altered body composition in the offspring.  In addition, this model can 
be utilized to determine mechanisms causing or regulating long-term outcomes in body 
composition.  Future studies will investigate impacts these maladaptations of body 
composition will have on metabolic disease risks, specifically glucose tolerance.
Because skeletal muscle and adipose tissue are key components of glucose disposal, one 
would suspect differences in body composition of female mice exposed to PCBs may 
predispose their offspring to impaired glucose tolerance at a young age and perhaps the 
male offspring too will display impairments in glucose tolerance as a result of their 
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decreased lean mass. My data clearly demonstrate that perinatal PCB exposure impacts 
body composition in young females and males of all ages, increasing adiposity and 
reducing lean body mass, respectively. Later life implications of such early PCB 
exposure and the development of obesity-associated pathologies remain uncertain.  
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Table 2.2 at 7 Weeks of Age
*,** Significantly different from 0 μmole/kg control, p<0.05 and p<0.01, respectively.
Mean 
(SEM)
Dose of PCB 126 
(μmole/kg)
0
(n=12)
0.5
(n=15)
1
(n=10) P
Body Weight (g) 29.33(0.80)
30.43
(0.71)
31.56
(1.41) 0.298
Fat Mass (g) 5.76(0.52)
6.91
(0.45)
8.57**
(0.94) 0.015
Fat (%) 19.37(1.21)
22.45*
(0.92)
26.54**
(1.93) 0.003
Lean Mass (g) 20.52(0.39)
20.69
(0.31)
20.33
(0.59) 0.830
Lean (%) 70.23(1.09)
68.23
(0.81)
65.00** 
(1.70) 0.017
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Table 2.3 at 7 Weeks of Age
*, ** significantly different from control, p<0.05 and p<0.01, respectively.
Mean 
(SEM)
Dose of PCB 126 
(μmole/kg)
0
(n=10)
0.5
(n=11)
1
(n=13) P
Body Weight (g) 39.58(1.64)
37.69
(0.91)
36.82
(1.45) 0.368
Fat Mass (g) 6.72(1.05)
7.20
(0.73)
6.76
(0.42) 0.876
Fat (%) 16.35(1.91)
18.80
(1.61)
18.28
(0.77) 0.476
Lean Mass (g) 28.51(0.64)
26.15*
(0.39)
25.68**
(0.91) 0.024
Lean (%) 72.59(1.83)
69.66
(1.49)
69.96
(0.82) 0.286
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Table 2.4 at 6 months of Age
Mean 
(SEM)
Dose of PCB 126 
(μmole/kg)
0
(n=12)
0.5
(n=15)
1
(n=11) P
Body Weight (g) 45.83(2.26)
46.39
(2.14)
47.01
(2.25) 0.938
Fat Mass (g) 16.33(1.80)
17.51
(1.74)
18.82
(1.53) 0.629
Fat (%) 34.49(2.42)
36.33
(2.42)
39.46
(1.54) 0.365
Lean Mass (g) 25.23(0.59)
24.55
(0.51)
24.18
(0.83) 0.529
Lean (%) 55.97(1.91)
54.05
(1.96)
51.87
(1.19) 0.313
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Table 2.5 at 6 months of Age
*, ** significantly different from control, p<0.05 and p<0.01, respectively.
Mean 
(SEM)
Dose of PCB 126 
(μmole/kg)
0
(n=10)
0.5
(n=13)
1
(n=12) P
Body Weight (g) 54.55(1.69)
48.80*
(1.67)
47.39*
(2.34) 0.043
Fat Mass (g) 13.49(0.89)
11.72
(1.57)
11.97
(1.34) 0.724
Fat (%) 24.18(1.26)
23.16
(2.56)
24.87
(2.42) 0.896
Lean Mass (g) 35.03(0.92)
31.39*
(0.73)
29.73** 
(1.45) 0.007
Lean (%) 64.74(1.30)
65.01
(2.17)
63.11
(2.00) 0.835
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Table 2.6 at 9 months of Age
Mean 
(SEM)
Dose of PCB 126 
(μmole/kg)
0
(n=12)
0.5
(n=15)
1
(n=9) P
Body Weight (g) 52.43(1.84)
51.91
(2.64)
52.93
(2.74) 0.960
Fat Mass (g) 22.69(1.50)
23.03
(2.17)
24.35
(1.69) 0.723
Fat (%) 42.78(1.43)
42.48
(2.83)
45.74
(1.19) 0.334
Lean Mass (g) 26.24(0.41)
25.55
(0.59)
25.27
(1.13) 0.944
Lean (%) 50.48(1.27)
50.73
(2.29)
47.92
(0.84) 0.414
 
 
47
 
Table 2.7 at 9 months of Age
*, ** significantly different from control, p<0.05 and p<0.01, respectively.
Mean 
(SEM)
Dose of PCB 126 
(μmole/kg)
0
(n=10)
0.5
(n=12)
1
(n=10) P
Body Weight (g) 55.50(2.02)
51.78
(1.72)
47.96
(2.47) 0.058
Fat Mass (g) 13.44(1.43)
14.22
(1.39)
13.03
(1.74) 0.848
Fat (%) 23.67(2.06)
26.85
(2.10)
26.83
(3.28) 0.601
Lean Mass (g) 36.24(0.83)
32.18*
(0.62)
30.08** 
(1.85) 0.004
Lean (%) 65.74(1.66)
62.68
(1.73)
62.91
(2.56) 0.459
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Figure 2.1 Maternal PCB 126 Exposure and Body Weight. A) Schematic diagram of 
exposure model.  Dams were administered 0, 0.5 or 1.0 μmole of PCB 126 per kg body 
weight via oral gavage every 14 days beginning 48 hours prior to mating until 
approximately postnatal day 7, for a total of 3 exposures. Females were allowed to mate 
for 7 days; therefore, the exact developmental day of exposure was unknown.  Day 0 
signifies date of birth.  Litters were delivered over a span of 7 days.  Mice were weaned 
on postnatal day 21. B) Maternal body weight.  Dam body weights were taken weekly 
prior to mating.  During mating and gestation, dam body weights were taken daily until 
birth and again beginning on postnatal day 3 until weaning.  There were no differences in 
maternal body weight between treatment groups (p=0.459).
Copyright © Cetewayo Saif Rashid 2013
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CHAPTER 3
SEX-SPECIFIC IMPAIRMENTS OF GLUCOSE TOLERANCE AS A 
CONSEQUENCE OF PERINATAL POLYCHLORINATED BIPHENYL 
EXPOSURE 
3.1 Abstract
Diabetes rates are increasing alarmingly. There is experimental evidence that 
environmental pollutants may be involved in diabetes etiology and there are plastic 
developmental periods in which xenobiotic exposure can have long term consequences 
on health. The present study investigated the effects of maternal polychlorinated biphenyl 
(PCB) exposure on offspring glucose homeostasis.  Female CD-1 mice were orally 
gavaged biweekly with vehicle (safflower oil) or 1 μmole/kg coplanar PCB 126 
beginning 48 hours prior to mating until weaning. Oral glucose tolerance tests were 
performed at 7 weeks, 6 and 9 months of age.  Male offspring displayed impaired glucose 
tolerance at only 7 weeks of age while female offspring exhibited impaired glucose 
tolerance at 6 and 9 months of age.  Interestingly, glucose intolerance in female offspring 
were dependent upon fasting time and route of glucose administration as prolonged 
fasting and intraperitoneal glucose administration resulted in glucose disposal rates 
comparable to control females.  Insulin tolerance test was performed at 8 months of age 
and neither males nor females perinatally exposed to PCB 126 had attenuated insulin 
sensitivity.  These data indicate sex-specific roles of perinatal PCB exposure on glucose 
homeostasis impairment.  Further studies are needed to elucidate mechanisms involved in 
maternal PCB exposure-induced hyperglycemia and should investigate splanchnic 
disruptions that may be involved. 
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3.2 Introduction
Polychlorinated biphenyls (PCBs) are a class of persistent organochlorine 
pollutants that partition with lipids and biomagnify in the food chain resulting in dietary 
exposure [173, 174, 278]. Since production of PCBs was banned in 1976 and remediation 
has been established, their levels in the environment are decreasing, and consequently, 
dietary exposure and body burdens are also decreasing. Paradoxically, the incidence of 
diabetes has increased alarmingly over the past several decades and while advancements 
in understanding the mechanisms of hyperglycemia have been made, diabetes etiology 
remains elusive [181, 232].  Associations of diabetes and environmental pollutants in the 
form of organochlorines have recently been uncovered, but the findings across studies 
have been inconsistent. 
Cross-Sectional studies of National Health and Nutrition Examination Survey
(NHANES) data show clear associations between Type 2 diabetes mellitus (T2DM) and 
serum PCB levels [260, 279-281]. Everette et al found that PCB 126 was associated with 
diagnosed or undiagnosed diabetes, and also associated with prediabetes with HbA1c 
5.9% - 6.4% [260, 279].  Turyk et al evaluated this association in Great Lakes fish 
consumers and found that dioxin-like PCBs but not total PCBs was associated with 
diabetes, but this finding did not hold true when adjusted for another organochlorine p,p’-
diphenyl dichloroethene (DDE) [93].  Transnational studies confirm this positive 
association between PCBs, particularly dioxin-like PCBs, and diabetes [282-286].  These 
observed associations may be explained by an attenuation of xenobiotic clearance in 
diabetics, therefore one cannot conclude that PCB exposure is involved in diabetes 
etiology.  Prospective studies are of better use in elucidating causality.  Prospective
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studies reveal increased risk of diabetes upon PCB exposure primarily in women [202,
287, 288]. However, two prospective case control studies failed to find an association 
between diabetes incidence and PCB levels; one was  conducted in middle-aged Swedish 
women using only PCB 153 as an indicator of PCB exposure and the other was 
conducted from the  Coronary Artery Risk Development in Young Adults (CARDIA)
cohort study [259, 289].  Taken together, epidemiological studies are suggestive of a role 
of PCB exposure in the etiology of diabetes, particularly in women.
Transplacental transport of PCBs has been reported, and PCBs have been found in 
cord blood and breast milk indicating early life exposure beginning in utero [182] [188].
In an attempt to explain the paradox of decreasing exposure and increasing diabetes 
incidence, Lee at al hypothesized that low level exposure in utero may have pronounced 
epigenetic effects mediating diabetes susceptibility [261].  In fact, PCB exposure has 
been shown to be associated with low birth weight in some studies, and it is now well 
established that low birth weight offspring have an increased risk of developing diabetes 
later in life [182, 184, 200, 230, 248, 249, 290].  Despite the growing evidence of the 
importance of PCB exposure on glucose homeostasis, there are no reported investigations 
of perinatally exposed offspring and later life glucose tolerance.  
In the present study, we employed a rodent model of perinatal PCB exposure 
which mimics body composition effects in young humans perinatally exposed to PCBs 
[291]. Previously, I have shown that mice born to dams exposed to a biweekly regimen 
of 1 μmole/kg PCB 126 displayed increased adiposity and decreased lean mass in female 
and male offspring, respectively.  These alterations in body composition could have an 
impact of glucose tolerance, as increased adiposity may cause insulin resistance and 
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subsequent hyperglycemia.  Additionally, a reduction in lean mass could also confer 
hyperglycemia as skeletal muscle is primarily responsible for glucose excursion.  In the 
present study, I found that PCB exposure during the critical periods of periconception, 
gestation, and lactation engenders sex-specific and age-dependent perturbations of 
glucose homeostasis.
3.3 Materials and Methods
3.3.1 Animals and Diets The experiments were performed in accordance with an 
approved Institutional Animal Care and Use Committee protocol at the University of 
Kentucky.  Experimental dams and offspring are the same as those in a published 
manuscript [291]. In summary, female ICR mice which had previously delivered one 
litter were purchased from Taconic at approximately 4 months of age.  Dams were 
maintained on a low fat 10% Kcal diet (D12450B, Research Diets, New Brunswick, NJ) 
ad libitum for duration of study.  One ICR sire was mated to two dams for one week.  
Pups were culled to 6 on postnatal day 3 and cross-fostering was employed whose litters 
had less than 6 pups to equilibrate nutrient availability.  Mice were weaned onto standard 
chow (#2018, Teklad Global 18% Protein Rodent Diet) at 3 weeks of age and males were 
housed 3 per cage, and females were housed 5 per cage.  
3.3.2 PCB exposure PCB 126 (3, 3’, 4, 4’, 5-pentachlorobiphenyl) was purchased from 
AccuStandard (C-126N, New Haven, CT).  Dams were treated with either tocopherol-
stripped safflower oil (vehicle) or 1 μmole/kg PCB 126 biweekly beginning 48 hours 
prior to mating  [291].
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3.3.3 Glucose tolerance test For all experimental procedures performed on offspring, 
only one male and one female per litter were used. At 7 weeks, 6 months, and 9 months 
of age glucose tolerance tests were performed on the offspring.  Mice were fasted prior to 
glucose tolerance tests beginning at lights on.  During glucose tolerance tests, mice were 
either orally gavaged (OGTT) or injected intraperitoneally (IPGTT) with 2 g/kg Dextrose 
(Bimeda, Le Sueur MN). Blood glucose was measured by tail vein venipuncture using an 
Ascensia Breeze 2 meter (Bayer, Mishawaka, IN) just prior to dextrose administration for 
baseline measurement.  Blood was sampled again 15, 30, 60 and 120 minutes after 
glucose administration.  For glucagon like peptide-1 (GLP-1) receptor antagonist studies, 
Exendin Fragment 9-39 (Ex-9) was purchased from Sigma (E7269) and administered at a 
dose of 5 μg in 200 μl sterile PBS 30 minutes prior to oral glucose tolerance test.
3.3.4 Insulin tolerance test Recombinant human insulin (Novolin) was used for insulin 
tolerance tests.  Males and females were given 1.25 and 0.75 IU/kg insulin diluted in 
sterile phosphate buffered saline (PBS) intraperitoneally (IP), respectively.  Mice were 
fasted at lights on for 3 hours prior to insulin administration.  Blood glucose was 
measured via glucometer just prior to insulin administration and again 15, 30, 60, 120 
and 180 minutes after insulin injection.  
3.3.5 Pyruvate tolerance test Pyruvate tolerance tests were performed to indicate rate of 
gluconeogenesis.  Pyruvate dissolved in sterile saline was injected IP at a concentration 
of 2 g/kg after 3 hours of fasting into female offspring.  Blood glucose was measured in 
tail vein every 30 minutes for 3 hours.  Again, the baseline measurement was taken just 
prior to pyruvate administration.  
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3.3.6 Statistics IBM SPSS statistics 20 software was used for repeated measures 
ANOVA for determining significance in experiments in which repeated samples were 
taken from a single mouse, as in the case of glucose, insulin and pyruvate tolerance tests.  
In the case that repeated measures identified a significant difference between groups, then 
OneWay ANOVA was performed for comparing the treatment groups at each time point.  
Areas under the curve were determined by SigmaPlot 12.0 software.  Grubbs’ Test was 
performed using GraphPad software to identify significant outliers which were excluded 
from further statistical analyses.  Those animals whose area under the curve (AUC) was a 
significant outlier were removed for subsequent statistical analyses.  Students T-test was 
used to determine significance between the areas under the curve of treatment groups.
3.4 Results
3.4.1 PCB-induced disruption of glucose homeostasis in gender specific and time-
dependent At 7 weeks of age a glucose tolerance test was performed on both male and 
female offspring following a 3 hour fast.  Male offspring displayed differences in glucose 
homeostasis (Figure 3.1A).  Upon an oral glucose challenge, maternal PCB exposure 
resulted in impaired glucose tolerance in male offspring compared to controls. The AUC 
between the males born to dams exposed to 1 μmole/kg PCB 126 was increased 31% 
compared to controls, p=0.041 (Figure 3.1B) signifying attenuation of glucose disposal 
more than 4 weeks after the last perinatal PCB exposure.  The PCB-exposed female 
offspring showed a trend toward impaired glucose disposal upon the experimental oral 
glucose challenge (Figure 3.1C) (p=0.069 and 0.162 for repeated measures ANOVA and 
AUC T-test, respectively). The female offspring born to PCB-exposed dams also had 
significantly elevated fasting blood glucose values.
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At six months of age, both male and female offspring were fasted for 3 hours 
prior to administering oral glucose tolerance tests.  Male offspring revealed no difference 
in glucose tolerance upon an oral glucose challenge (Figure 3.2A and 3.2B).  The females 
born to dams perinatally exposed to 1 μmole/kg PCB 126 displayed impaired glucose 
tolerance, p=0.038 and p=0.055 for repeated measures ANOVA and AUC T-test, 
respectively (Figure 3.1D).  Perhaps with a larger sample size, the AUC would have 
demonstrated statistically significant impairment in glucose homeostasis as well.
The male offspring control animals after 6 months of age displayed an 
overabundance of variability rendering it impossible to discern any statistically 
significant difference between them and PCB-exposed offspring regarding glucose 
tolerance.  For this reason, male glucose tolerance data were not analyzed after 6 months 
of age and subsequent glucose tolerance tests were performed only on females born to 
vehicle and 1 μmole/kg PCB 126 exposed dams (Figures 3.4 and 3.5).
3.4.2 Insulin tolerance is comparable between treatment groups Insulin tolerance tests 
were employed to investigate whether impairments in glucose disposal were the result of 
insulin resistance.  Blood glucose was monitored in both male and female offspring at 8 
months of age following IP injection with insulin.  Both sexes experienced declines in 
blood glucose at similar rates between vehicle and PCB exposed groups (Figure 3.3).
Male offspring born to vehicle treated dams appeared to have higher levels of blood 
glucose beginning at baseline and continuing throughout the tolerance test, but the 
amount of variability in the controls made any difference statistically insignificant.  The 
results from the insulin tolerance tests eliminate insulin resistance as an underlying 
mechanism of perinatal PCB-induced hyperglycemia.
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3.4.3 Fasting time and route of glucose administration affect glucose tolerance in female 
offspring In aged females, glucose intolerance persisted in PCB exposed mice and was 
shown to reach statistical significance at 9 months of age (Figure 3.4).  Interestingly, 
disruption of glucose homeostasis was only observed when the glucose was administered 
orally after a 3 hour fast (Figure 3.4A and 3.4B) because when glucose was injected IP, 
there were comparable glucose disposal rates between vehicle and PCB exposed 
offspring (Figure 3.4C).  Additionally, when aged female offspring were administered 
glucose orally following an overnight 16 hour fast, there were again comparable rates of 
glucose disposal (Figure 3.4D). Taken together, these data illustrate disruption of an 
early event in glucose ingestion, one that occurs most likely prior to glucose appearance 
in the blood stream.  This is further evidenced by the observation that the earliest time 
point after glucose challenge is the most severely impaired.
3.4.4 GLP-1 receptor antagonism does not extinguish PCB-induced glucose intolerance 
in female offspring Exendin Fragment 9-39 (Ex 9) is a competitive antagonist of the 
GLP-1 receptor.  GLP-1 is secreted by L cells of the gut after a meal and signals in an 
endocrine fashion to slow gastric emptying and augment glucose-stimulated insulin 
secretion. The impairment in glucose tolerance is at the earliest time point, suggesting the 
bolus of glucose was absorbed into the bloodstream more quickly and completely in the 
female offspring born the PCB exposed dams than in the controls. Because GLP-1 slows 
gastric emptying, if impaired GLP-1 signaling was contributing to glucose intolerance, 
antagonism of the GLP-1 receptor would diminish glucose intolerance and result in 
comparable glucose tolerance curves, particularly at the 15 minute time point. The GLP-
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1 receptor was inhibited by Ex-9 30 minutes prior to commencement of an oral glucose 
tolerance test.  All mice were given Ex-9 due to the small sample size and inherent 
variability of the experiment.  The effect of the Ex-9 was seen by the nearly identical 
43% and 45% increase in blood glucose in the 30 minutes between Ex-9 injection and 
glucose administration.  GLP-1 receptor antagonism mitigated much of the disturbance in 
glucose tolerance following an oral glucose challenge, p=0.225 and 0.468 for repeated 
measures and AUC, respectively.  Antagonism of the GLP-1 receptor appeared to 
extenuate glucose intolerance yet the large impairment at 15 minutes post gavage 
remained, p=0.016 at that time point (Figure 3.5A).
3.4.5 Rate of gluconeogenesis is not different after 3 hour fast Hepatic glucose 
production (HGP) consists of glycogenolysis and gluconeogenesis, the latter utilizing 
pyruvate for de novo synthesis of glucose to be taken up by the periphery.  The pyruvate 
tolerance test functions as an indirect measure of gluconeogenesis.  Because glucose 
intolerance was observed after 3 hours of fasting and not 16 hours, this approach was 
used to investigate early initiation of HGP as a contributor to the glucose intolerant 
phenotype of perinatally PCB exposed female offspring.  Figure 3.5B illustrates 
comparable blood glucose levels after pyruvate administration following a 3 hour fast, 
p=0.465 and 0.449, for repeated measures and AUC, respectively.
3.5 Discussion
The impairment in glucose tolerance observed at 7 weeks of age in perinatally 
exposed male offspring is likely due to direct exposure of PCBs through the breast milk.  
The partitioning of PCB 126 in goat kids upon maternal PCB exposure during gestation 
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and lactation revealed undetectable serum levels at birth but modest amounts at weaning 
[188].  Additionally, at 40 weeks of age, goat kids showed sequestration of PCB 126 in 
the liver as compared to adipose tissue and they determined its half-life to be 4 months 
[188]. Baker et al showed direct exposure of dioxin-like PCBs 77 and 126 elicit glucose 
intolerance and insulin resistance in male C57BL/6 mice [186].  Because insulin 
tolerance tests were not performed on the male offspring at the time of glucose 
intolerance, we cannot ascertain the role of insulin in PCB-induced hyperglycemia.
Female offspring born to PCB-exposed dams exhibited glucose intolerance at 
older ages, suggesting PCB-induced fetal programming of glucose intolerance rather than 
direct effects of PCB on glucose homeostasis. Impairment in glucose tolerance in female 
offspring upon an oral glucose challenge but not an IP glucose challenge, as well as its 
sensitivity to changes in fasting time, point to splanchnic system dysfunction rather than 
insulin resistance [192]. The insulin tolerance test results are evidence that perinatal PCB 
exposure does not impair insulin sensitivity.  This is corroborated by Lee et al. who 
showed in a 2007 analysis of 1999-2002 NHANES data, that dioxin-like PCBs are not 
associated with HOMA-IR, an index of insulin resistance, in non-diabetic Americans 
[121]. Additionally, a case control study found no association between reference PCB 
153 and insulin-dependent diabetes [292]. In further support of this is the fact that 
glucose reaches the pancreas in both routes of glucose administration, such that if there 
were impairment in glucose-stimulated insulin secretion, the disruption should be 
observed in both oral and IP glucose tolerance tests.  
The pyruvate tolerance test reveals that gluconeogenesis is not affecting glucose 
tolerance, deducing hepatic glucose uptake as possible underlying mechanism of the 
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observed hyperglycemia.  Studies have shown an involvement of the AhR in the 
development of the hepatic vasculature, specifically “failure of ductus venosus closure” 
resulting in hypoperfusion of the liver [293, 294]. If this effect of the AhR on liver 
development follows a U-shape, characteristic of endocrine disruptors, then it is possible 
that over activation of the receptor, too, could result in hepatic hypoperfusion and 
attenuated HGU.  This phenomenon is also observed in hypoxic intrauterine growth 
restricted fetuses in order to spare nutrients for the proper development of more important 
organs like the brain [194, 226].
In conclusion, humans are exposed to persistent organic pollutants such as PCBs 
in our first environment, the womb of our mothers.  Although this exposure continues for 
most likely the duration of our lives, the ramifications of early life pollutant exposure 
may not manifest until later in life.  The present study demonstrated perturbations of PCB 
exposure on later life glucose homeostasis in both male and female offspring born and 
nursed to PCB exposed dams.  More studies are needed to assess the contribution of pre-
weaning xenobiotic exposure on the etiology of diabetes.
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Figure 3.1. OGTT in offspring at 7 weeks of age.  Mice were orally gavaged with 2 g/kg 
glucose after 3 hour fast. A) OGTT in male offspring; n=11 and n=12 for Control and 
PCB groups, respectively.  Repeated measures p=0.038 B) Area under curve for OGTT 
of male offspring, p<0.05. C) OGTT in female offspring; n=11 and n=10 for Control and 
PCB groups, respectively.  Repeated measures p=0.069. D) Area under curve for OGTT 
of female offspring. * indicates p<0.05 and ** indicates p<0.01.
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Figure 3.2. OGTT in offspring at 6 months of age.  Mice were orally gavaged with 2 g/kg 
glucose after 3 hour fast. A) OGTT in male offspring; n=10 and n=11 for Control and 
PCB groups, respectively.  Repeated measures p=0.494 B) Area under curve for OGTT 
of male offspring. C) OGTT in female offspring; n=11 and n=11 for Control and PCB 
groups, respectively.  Repeated measures p=0.038. D) Area under curve for OGTT of 
female offspring, p=0.055. * indicates p<0.05.
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Figure 3.3. ITT in offspring at 8 months of age.  Mice were fasted for 3 hours prior to 
insulin administration. A) Male offspring were IP injected with 1.25 IU/kg insulin; n=9
and n=10 for Control and PCB groups, respectively.  B) Female offspring were IP 
injected with 0.75 IU/kg insulin; n=11 and n=10 for Control and PCB groups, 
respectively.  
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Figure 3.4. GTT in female offspring at 9 months of age.  A) OGTT in female offspring; 
n=11 and n=9 for Control and PCB groups, respectively.  Repeated measures p=0.019 B) 
Area under curve for OGTT of female offspring, p<0.05. C) IPGTT in female offspring; 
n=12 and n=9 for Control and PCB groups, respectively. D) OGTT of female offspring
following an overnight (16 hour) fast; n=12 and n=9 for Control and PCB groups, 
respectively. * indicates p<0.05.
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Figure 3.5. Splanchnic investigation. A) Female mice 1 year of age were administered 
GLP-1 receptor antagonist Ex-9 30 minutes prior to OGTT; n=12 and n=9 for Control 
and PCB groups, respectively.  Repeated measures p=0.225.  B) Pyruvate tolerance test 
was conducted on female offspring 1 year of age.  Mice were injected IP with 2 g/kg 
sodium pyruvate and blood glucose measured every half hour for 3 hours; n=12 and n=9
for Control and PCB groups, respectively.  * indicates p<0.05
Copyright © Cetewayo Saif Rashid 2013
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CHAPTER 4
MATERNAL PCB EXPOSURE AFFECTS HEPATIC GENE EXPRESSION OF 
MOUSE DAM AND OFFSPRING BOTH IN UTERO AND AT 4 MONTHS OF 
AGE
4.1 Abstract
Polychlorinated biphenyls (PCBs) are environmental pollutants whose 
bioaccumulation and transplacental transfer results in exposure during critical windows 
of development which may cause reduced birth weight.  The liver functions in 
macronutrient energy homeostasis and xenobiotic detoxification, and previous studies 
found changes in body composition and glucose tolerance upon perinatal PCB exposure.  
I therefore investigated effects of gestational PCB exposure on intrauterine growth and 
alterations in hepatic gene expression.  Female ICR/CD1 mice were gavaged biweekly 
with 1 μmole/kg PCB 126 or safflower oil vehicle.  In one cohort, females were 
euthanized at embryonic day 18 and pup and placental weights recorded.  Also, livers 
were harvested from both non-pregnant and pregnant dams and cesarean pups.  In a 
second cohort, dams were allowed to deliver and nurse their litters, and offspring livers 
were collected at 4 months of age (from breeding study in Aims 1-2). There were no 
differences in fetal body or placental weights.  Absolute mRNA quantification revealed 
upregulation of dipeptidyl peptidase 4 along with canonically aryl hydrocarbon receptor 
(AhR) regulated genes cytochrome P450 (Cyp) 1a1, Cyp1b1, NAD(P)H quinone 
oxidoreductase 1 (NQO1) and nuclear factor erythroid-derived 2-like 2 (Nrf2) in livers of 
non-pregnant females, dams, and cesarean pups.  PCB gavaged mice also displayed 
attenuated insulin-like growth factor binding protein 2 (IGFBP2) and alterations in genes 
involved in oxidative stress and macronutrient metabolism.  Four month old offspring 
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exhibited decreased insulin-like growth factor (IGF) 1 expression and increased 
expression of Cyp1a1 and stress related genes, autophagy related protein 7 (Atg7) and 
DNA damage-inducible transcript 3 (CHOP) without any detectable PCB in their livers.  
Key findings in the study are significant changes in hepatic gene expression in adult 
offspring perinatally exposed to PCB even in the absence of any detectable parent 
compound or metabolite; and PCB-induced regulation of genes linked to metabolic 
disease states, DPP4 and IGFBP2.
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4.2 Introduction
Polychlorinated biphenyls (PCBs) are a class of environmental pollutants whose 
lipophilicity and resistance to biodegradation enables biomagnifications in the food chain 
and resulting in lifetime of dietary exposure [181, 190].  PCB exposure begins in utero 
rather than after birth. These toxicants have been found in the placenta, cord blood and 
breast milk, signifying a continuum of exposure during perinatal development [278, 295-
299]. Many animal studies employing PCBs often begin exposure after birth, which is not 
entirely exemplary of the human experience in that it dismisses a critical period when
relatively small exposures are aggrandized and have potentially incessant repercussions.  
In fact, several studies in humans have correlated prenatal PCB exposure with low birth 
weight in offspring indicating PCB-induced developmental perturbations [182, 199, 200,
248-251].
Moreover, dioxin and dioxin like PCBs activate the AhR and studies have 
demonstrated a role of this xenobiotic receptor in hepatic organogenesis with AhR 
deficient animals exhibiting aberrant hepatic histology and attenuated perfusion [300-
304]. Because the liver is the site of xenobiotic detoxification and central to energy 
homeostasis, I sought to investigate alterations of hepatic gene expression in murine 
offspring perinatally exposed to 3,3’,4,4’,5 pentachlorobiphenyl (PCB 126).  
The classical and most studied ligand of the AhR is 2,3,7,8-tetrachlorodibenzo-p-
dioxin (TCDD) or more commonly referred to as simply dioxin.  Several studies have 
examined dioxin-induced alterations of hepatic gene expression [305-316].  Both in vitro 
and in vivo experiments confirm dioxin mediated induction of classical AhR responsive 
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genes cytochrome P450, 1a1 (Cyp1a1), 1b1 (Cyp1b1), and NAD(P)H dehydrogenase 
quinine 1 (NQO1) but genes involved in energy homeostasis and oxidant metabolism 
may be species and cell source specific [309, 311, 313-316]. AhR binding and nuclear 
translocation necessitates dioxin-induced hepatotoxicity and consequently studies have 
focused on dioxin-induced gene expression mediated by ligand binding [317-319].
However, Tijet et al in their investigation of TCDD-induced gene batteries demonstrated 
that some genes are regulated by AhR independent of TCDD, while others are regulated 
by TCDD when AhR is lacking, illustrating transcriptional modulation in the absence of 
canonical ligand:receptor activation [310].
Ovando et al. compared hepatic toxicogenomic effects of TCDD, PCB 126, and 
non-dioxin-like PCB 153 using a chronic exposure model in female Sprague Dawley rats.  
The rats were exposed to 100 ng/kg/day TCDD, 1000 ng/kg/day PCB 126, or 1000 
μg/kg/day PCB 153 5 days per week for 13 or 52 weeks and of the 75, 70, and 9 genes, 
respectively, that were significantly regulated upon toxicant exposure at both time points, 
only 42 were shared between TCDD and dioxin-like PCB 126 [320].  These data 
accentuate the flaw in extrapolating dioxin-induced gene expression to dioxin-like PCB-
mediated gene expression.  Additionally, these studies fail to elucidate alterations in 
hepatic gene expression during fetal and postnatal development which contains critical 
periods of anatomical and epigenetic progression.  As a result, PCB exposure during 
these windows of plasticity will likely exhibit changes in gene expression secondary and 
perhaps tertiary to AhR activation resulting from perturbed development.  Previous 
studies employing this low dosing PCB exposure model have revealed sex-specific 
alterations in offspring body composition, and unpublished glucose and insulin tolerance 
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data alludes hepatic dysfunction.  In the current experiment, I showed biweekly PCB 126 
exposure at 1 μmole/kg alters hepatic gene expression in dam, fetal and offspring livers.
4.3 Methods: 
4.3.1 PCB exposure during pregnancy These experiments were performed with the 
approval of the Institutional Animal Care and Use Committee at the University of 
Kentucky.  Female CD1 mice were acquired from Taconic at approximately 4 months of 
age after having previously delivered one litter. Mice were fed a semi-purified low fat 
diet, 10% Kcal from fat (Research Diets D12450B) ad libitum beginning 2 weeks prior to 
mating.  Male CD-1 breeders were also purchased from Taconic, and were fed low fat 
diet prior to mating.  48 hours prior to mating, female dams were exposed to male 
bedding in order to induce estrous.  Female mice were then placed in the cage of a male 
breeder.  Mating was permitted to commence overnight, at which time male mice were 
removed.  On embryonic day zero dams were gavaged with 1 μmole/kg PCB 126 
(AccuStandard, C-126N New Haven, CT) dissolved in tocopherol-stripped safflower oil 
(Dyets # 403952 Bethlehem, PA). A second dose was administered 14 days after the first 
oral exposure.  This exposure was then on embryonic day 14. On embryonic day 18.5, 
mice were sacrificed, and there was no dam that delivered her litter prior to takedown.  
Livers were taken from both pregnant and non-pregnant dams.  Also, the number of 
fetuses per dam was counted.  Fetuses were weighed as well as their respective placentas.  
Livers were excised from the 2 most distal fetuses on each uterine horn as the position of 
the fetus within the uterus affects nutrient availability and perhaps subsequent hepatic 
gene expression.  Tissues were snap frozen in liquid nitrogen until further processing.
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4.3.2 PCB exposure of 4 month old offspring In a separate cohort of mice (same breeding 
paradigm as Aim 1 and 2), female ICR mice which had previously delivered one litter 
were purchased from Taconic at approximately 4 months of age.  Dams were maintained 
on a low fat 10% Kcal diet (D12450B, Research Diets, New Brunswick, NJ) ad libitum 
for duration of study.  One ICR sire was mated to two dams for one week.  Dams were 
exposed bi-weekly to tocopherol-stripped safflower oil (vehicle) or 1 μmole/kg PCB 126 
from 48 hours prior to mating until weaning.  Pups were culled to 6 on postnatal day 3 
and cross-fostering was employed whose litters had less than 6 pups to equilibrate 
nutrient availability.  Mice were weaned onto standard chow (#2018, Teklad Global 18% 
Protein Rodent Diet) at 3 weeks of age and males were housed 3 per cage and females 
were housed 5 per cage.  In this separate cohort, mice were mated for 1 week rather than 
overnight, therefore the day of gestation which dams were gavaged cannot be determined.  
At 4 months of age, a group of these mice were sacrificed; livers were collected and snap 
frozen until further processing.
4.3.3 PCB quantification Approximately 45 mg of liver was homogenized in 200 μl 
deionized water using 3 stainless steel 5/32” grinding balls and Geno/Grinder (SPEX 
Sample Prep) at 1250 rpm for 45 seconds. Eight hundred microliters of cold acetonitrile 
and 50 μl of 10μM 13C labeled PCB 126 were added to homogenate with the latter 
serving as an internal standard.  This solution was vortexed for 5 minutes, sonicated for 
30 seconds in water bathe sonicator, then centrifuged for 5 minutes at 15,000 rpm.  
Superntant was transferred to a glass vial.  This disruption was repeated on the pellet 
twice with 1 ml cold acetonitrile and 1 ml 50% cold acetonitrile, respectively.  
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Supernatants were pooled, dried under nitrogen and reconstituted in 100 μl of 99/1 
methanol/water + 0.5% formic acid + 0.1% ammonium formate solution.
Liquid chromatography-tandem mass spectrometry of the reconstituted samples 
from vehicle and PCB exposed animals was performed by Manjula Sankara under the 
supervision of Dr. Andrew Morris.  The following is their protocol for this procedure.
PCB 126 and hydroxy PCB 126 were measured using a Shimadzu 
UFLC coupled with an AB Sciex 4000-Qtrap hybrid linear ion trap triple 
quadrupole mass spectrometer in multiple reaction monitoring (MRM) 
mode. 13C12 PCB 126 was used as internal standard for PCB 126 and 
hydroxy PCB 126 measurements. The mass spectrometer was operated in 
the positive APCI mode for PCB 126 measurements and in negative ESI 
mode for hydroxy PCB 126 measurements with optimal ion source settings 
determined by synthetic standards. PCB 126 was analyzed using Kinetex 
2.6 u C18, 100 A, 100 X 2.10 mm (Phenomenex) column. The mobile 
phase consisted of water as solvent A and acetonitrile as solvent B. For 
the analysis of PCBs the separation was achieved using a gradient of 20 
% B to 60 % B for 1 min, 60% B to 100% B in the next 7 min, and 
maintained at 100% B for the last 2 min with a flow rate of 0.25 ml/min. 
MRM transitions monitored were as follows: 325.9/256.1; 325.9/254.1 
and 325.9/184 for PCB 126; and 338/268.1; 338/196.1 and 338/265.7 for 
13C12 PCB 126. In the MRM ion transition the precursor ion represents 
the M · and the product ion represents either [M-Cl] or [M-2Cl] .
Hydroxy PCB 126 was analyzed using Luna 3 u C18 (2), 100 A, 250 X 
2.00 mm (Phenomenex) column with a flow rate of 0.25 mL/min. The 
mobile phase consisted of 75/25 of methanol/ water with formic acid 
(0.5%) and 5 mM ammonium formate (0.1%) as solvent A and 99/1of 
methanol/ water with formic acid (0.5%) and 5 mM ammonium formate 
(0.1%) as solvent B. Hydroxy PCB 126 was eluted using a gradient of 10 
% B to 100 % B in 4 min and maintained at 100% B for the next 11 min. 
MRM transitions monitored were as follows: 340.8/340.9 for hydroxy 
PCB 126 and 386.8/340.9 for dihydroxy PCB 126. Precursor ion of the 
ion transition is a formic acid adduct: [M+FA-H]- and product ion is [M-
H]-.
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4.3.4 RNA isolation Total RNA was extracted from liver samples using either Qiagen 
RNeasy mini kits or Qiagen RNeasy lipid tissue mini kit.  Approximately 30mg of tissue, 
three stainless steel 5/32” grinding balls and appropriate volume lysis buffer as indicated 
in the instructions was added to 2 ml tubes.  Samples were disrupted and homogenized 
using Geno/Grinder (SPEX Sample Prep) at 1250 rpm for 30 seconds.  Total RNA was 
silica-membrane purified from lysed homogenate according to manufacturer’s protocol.  
Tissue RNA quality was determined using Bioanalyzer and only RNA with an RNA 
Integrity Number above 7 was used for Nanostring gene expression analysis.  
4.3.5 Nanostring gene expression Nanostring technology uses capture and reporter 
probes specific to an mRNA sequence in a codeset to quantify the number of message 
RNA in a given sample.  This technology can quantify over 500 genes in a given sample 
simultaneously in a given codeset. We picked over a hundred genes to investigate 
changes in hepatic gene expression across the stages of development.  We used 2 
different codesets and 2 different quantities of RNA. For a complete list of genes in each 
codeset, reference Tables 4.8 and 4.9. One hundred nanograms of RNA were run on the 
first codeset in which RNA from pregnant dam and fetal livers were used.  On the second 
codeset, 750 nanograms of RNA from non-pregnant dam livers and 4 month old offspring 
livers were used.  All of the target genes in the first codeset that showed significant 
changes in gene expression were included in the second codeset, along with several 
others.  
4.3.6 Quantification of gene expression Manipulation of the raw counts from Nanostring 
was required to take into account variability in the amount of RNA used, and also the 
relative expression to housekeeping genes.  To do this, the sums of the positive controls 
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for each sample were averaged.  The sums of the samples’ positive controls were then 
divided by this mean to obtain the first scaling-factor.  A samples’ count for a particular 
gene was then subtracted by its maximum negative control value and this difference was 
then multiplied by the first scaling factor.  Housekeeping genes whose p value between 
treatment groups was greater than 0.5 and whose coefficient of variation across treatment 
groups was determined to be less than 0.5 were selected as reference genes.  For each 
sample, the geometric mean of the reference genes were calculated and averaged across 
samples.  This mean was then divided by the sample’s respective geometric mean to 
obtain the second scaling factor.  The adjusted counts were then multiplied by this second 
scaling factor, and it is these final values that were used in statistical analyses of gene 
expression.
4.3.7 Quantitative Real-time PCR Quantitative Real-Time PCR (qPCR) was performed 
to validate NanoString nCounter results.  Four hundred nanograms of RNA were reverse 
transcribed using qScript cDNA SuperMix (Quanta Biosciences 95048).  Primers were 
purchased from Eurofins MWG Operon (Table 4.8). Real-Time PCR was performed 
using PerfeCta SYBR Green FastMix Low Rox (Quanta Biosciences 101414) master mix 
and Stratagene Mx3000P real-time instrument.  The 2 CT method was used to calculate 
the relative quantity (RQ) with the mean of control samples as the calibrator.  
4.3.8 Statistics Fetal and placental weights were averaged such that each dam had an 
average fetal weight and an average placental weight, and these means were used in 
statistical analyses of pregnant dam parameters (Table 4.1).  Students T-test was used to 
make comparisons between PCB treated and control animals.  Interactions between 
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gender and PCB treatment were determined using 2way-ANOVA in SigmaPlot 12.0 
software.
4.4 Results
4.4.1 PCB treatment does not affect fetal or placental weights Biweekly PCB 126 
exposure did significantly affect dam, fetus, or placenta weights (Table 4.1).  There was 
however a trend toward increased placenta weights upon PCB exposure (p=0.07).  
Placental weights often correspond with birth weight, such that heavy babies have 
heavier placentas and small babies have lighter placentas.  This same trend is evident in 
this exposure model; PCB exposed fetuses weigh more than control fetuses, although this 
is difference is not statistically significant (p=0.226).  The decreased number of fetuses 
per dam may account for this slight increase in mean fetus and placenta weight, as parity 
affects fetal weight. My hypothesis that PCB exposure would cause lower birth weight 
did not come to fruition in this mouse model and PCB dosing paradigm, if one is to 
extrapolate the data from late gestation.
4.4.2 Quantification of PCB 126 and hydroxyl metabolite Figure 4.1 displays amount of 
parent compound detected in the livers of the samples tested.  Female mice gavaged with 
PCB that did not become impregnated had the highest average liver burden of parent 
compound at 20.96 pmol/mg wet weight, followed by pregnant dams at 6.16 pmol/mg 
with 1 of 9, and 6 of 9 samples having PCB levels below the limit of detection, 
respectively.  Only 1 of 9 fetal livers had detectable PCB 126 and its concentration was 
53.52 pmole/mg.  PCB levels in control animals were all below the limit of detection.  
Moreover, there was no hydroxy-PCB metabolite detected in any of the samples.
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4.4.3 Differential gene expression in dams administered PCB 126 PCB exposure during 
pregnancy resulted in 25 of 120 genes being differentially expressed.  The first codeset 
primarily included genes involved in detoxification, stress response, epigenetics and lipid 
and carbohydrate metabolism.  Table 4.2 shows the genes that were changed upon PCB 
126 exposure during pregnancy.  The genes are arranged in ascending order regarding the 
PCB/control ratio, beginning with the genes most downregulated and ending with the 
genes most upregulated.  This is the arrangement for all of the gene expression tables.  
Maternal PCB 126 increases expression of detoxifying enzymes Cyp1a1 and Cyp1b1 as 
is expected upon AhR activation.  Furthermore, Nuclear factor erythroid-derived 2-like 2
(Nrf2) and NAD(P)H quinone reductase 1 (NQO1) are increased, signifying interplay 
between the Nrf2 and AhR transcription factors [225, 321].  In addition to xenobiotic 
detoxifying cytochrome P450s being increased upon PCB exposure, antioxidative gene 
expression was increased (glutathione-s-transferase a1 (Gsta1), glutathione-s-transferase 
mu 4 (Gstm4), glutathione peroxidase (Gpx1), and catalase (Cat)). The majority of genes 
whose expression was decreased were involved in lipid metabolism e.g. perilipin 2 
(Plin2), carnitine palmitoyltransferase 1a (CPT-1A), acetyl-CoA carboxylase 1 (ACC1),
and peroxisome proliferator-activated receptor alpha ( However, other genes such 
as insulin-like growth factor (IGFBP2) and lactase dehydrogenase A (LDHA) were also 
decreased.  
4.4.4 Non-pregnant mice display modulation of macronutrient metabolism PCB exposed 
female mice that did not get pregnant revealed interesting gene expression patterns as 
well.  Of the 129 gene included on the 2nd codeset, 26 were changed upon PCB exposure.  
Again, cytochrome P450 enzymes involved in xenobiotic detoxification, Cyp1a1 and 
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Cyp1b1, as well as Nrf2 and NQO1 were significantly increased compared to controls.  
Genes involved in lipid homeostasis were attenuated, including fatty acid synthase (Fasn)
and ACC1 and glucose-6-phosphate dehydogenase (G6PD). There appears to be an 
increase in glucose uptake in the PCB exposed tissues as glucose transporter 1 (GLUT1)
is significantly increased.  GLUT2 is increased by 13% compared to controls also, 
although this increase is not statistically significant, p=0.060.  Increases in glycolytic 
genes hexokinase 3 (HK3) and phosphoglycerate kinase 1 (Pgk1) indicate possible 
increased glycolysis, but the decreased expression of glycogen synthase 2 (Gys2) and 
glycogen phosphorylase (Pygl) suggest neither glycogen synthesis nor glycogenolysis is 
increased, respectively.  Glycogen synthesis however is not particularly transcriptionally 
regulated, as phosphorylation events related to insulin and glucagon signalling are 
responsible for regulation of glycogenesis [6, 23].  The decreased expression of G6PD 
also suggests less divergence of phosphorylated glucose to the pentose phosphate 
pathway.  Figure 4.2 is a Venn diagram of the genes that are differentially expressed in 
pregnant and non-pregnant mice. The genes expressed in both pregnant and non-pregnant 
animals administered PCB are those involved in detoxification, either xenobiotic or 
oxidative.  
4.4.5 Fetal livers respond to PCB exposure in utero Any changes in fetal liver gene 
expression upon maternal PCB administration is either through direct transplacental 
exposure to the toxicants or a response to a disrupted intrauterine environment as a 
consequence of a maternal response to the dioxin-like PCB.  Table 4.4 displays genes that 
are significantly changed between those conceived by dams exposed to vehicle versus 
those exposed to 1 μmole/kg PCB 126.  Xenobiotic and oxidative detoxification genes 
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were increased in fetal livers maternally exposed to PCB including cytochrome P450s, 
Gstm4, NQO1, peroxiredoxin-1 (Prdx1), and Cu-Zn superoxide dismutase (SOD1), but 
genes involved in glucose homeostasis exhibited attenuated expression (GLUT1 and 
lactate dehydrogenase type A (LDHA)).  Figure 4.1 compares and contrasts gene 
expression among livers from non-pregnant and pregnant PCB exposed dams and the 
livers of fetuses.  Interestingly, excluding the 4 marker genes (Cyp1a1, Cyp1b1, Nrf2 and 
NQO1) only dipeptidyl-peptidase 4 (Dpp4) gene expression was increased.  Dpp4 plays a 
major role in glucose homeostasis by rapidly degrading the gut hormone, or incretin, 
glucagon-like peptide 1 (GLP-1) [32, 40, 322].  GLP-1 is secreted upon feeding and 
slows gastric emptying and potentiates glucose-stimulated insulin secretion [322, 323].
Increased Dpp4 expression and translation could augment glucose excursion and 
contribute to hyperglycemia.  Together, the upregulation of Cyp1a1, Cyp1b1 and NQO1 
point to direct activation of the fetal AhR and transactivation of these genes afforded by 
transplacental transport of PCB 126.
4.4.6 Maternal PCB exposure alters hepatic gene expression in 4 month old offspring
Recall that these offspring were born to dams that were exposed to PCB 126 forty-eight 
hours prior to mating and biweekly thereafter until weaning.  These offspring were thus 
exposed during lactation in addition to transplacental exposure in utero.  Alterations in 
hepatic gene expression persist in these animals.  Across gender, perinatal PCB exposure 
decreased expression of hypoxia-inducible factor 1a (Hif1a) and insulin-like growth 
factor 1 (IGF1) and increased expression of autophagy related protein 7 (Atg7), C/EBP 
homologous protein (CHOP), insulin-like growth factor 1 receptor (IGF1R), and Cyp1a1 
(Table 4.5).  The divergent expression of IGF1 and its receptor was likely compensatory.  
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CHOP and Atg7 are involved in endoplasmic reticulum stress and autophagy, 
respectively [324, 325].  Cyp1a1 expression suggests direct exposure to PCB 126 or 
constitutive activation of the AhR, perhaps mediated by epigenetic mechanisms. Both 
male and female offspring exhibit a general decrease in gene expression, Tables 4.6 and 
4.7, respectively.  Only four genes are different in male offspring born to vehicle or PCB 
exposed dams, and interestingly one is DNA methyltransferase 1 (Dnmt1).  If there were 
decreased DNA methylation in these livers, one might expect increased gene expression, 
but this is not the case.  Female offspring have 8 genes differentially expressed and only 
2 are upregulated, Nrf2 and Peroxisome proliferator-activated receptor gamma (Pparg).
Igf1 and the insulin receptor (Insr) are both decreased demonstrating a possible 
hypoproliferative or hypotrophic state in these livers.  Two-way ANOVA revealed 
significant interactions between gender and 5 genes, Insr, beta-2-microgobulin (B2m),
CPT1A, Prdx1, and the mineral corticoid receptor (MCR).  Only MCR was differentially 
expressed in males while the others were specific to females.  
4.4.7 NanoString nCounter results were validated with Real-Time PCR Quantitative 
real-time PCR was performed to validate gene expression. Cyp1a1 and NQO1 were 
selected as verifier genes because it was not feasible to perform RT-PCR for every gene 
that was changed and these 2 genes are expressed during canonical AhR activation.   
Real-time PCR shows changes in gene expression comparable to those observed using 
absolute mRNA quantification via NanoString nCounter (Table 4.9).   
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4.5 Discussion
The object of the present study was to elucidate changes in hepatic gene 
expression upon perinatal PCB exposure as may be secondary to PCB-induced 
intrauterine growth restriction and subsequent abnormal liver physiology.  The effects of 
PCB 126 on gene expression in livers was compared in female CD-1 mice, pregnant CD-
1 dams, gestational day 18.5 fetuses, and 4 month old male and female offspring.  Over 
one hundred genes were selected on 2 Nanostring codesets representing various 
biological processes, including but not limited to, xenobiotic and oxidant detoxification, 
inflammation, epigenetics, and metabolism of carbohydrates and lipids.  Also, to evaluate 
the contribution of ligand activated AhR-dependent gene transcription, PCB 126 was 
measured in these tissues.
Intrauterine growth restricted animals are often small in respect to their
gestational age and also small infants are usually accompanied by small placentas [326].
Because studies have shown that PCB exposure is inversely associated with birth weight, 
we hypothesized that gestational PCB exposure would result in fetuses and placentas that
were smaller at gestation day 18.5. In the present study, however, I did not observe 
statistically significant differences in fetal weight or placenta weight.  In fact, there were 
trends toward increased fetal and placental weights which are likely due a decrease in the 
number of fetuses per dam in the PCB exposed animals, although this too is not 
statistically significant.  One of the drawbacks to this animal model is that PCB levels in 
the dams are distributed across many fetuses, while in singleton offspring this not the 
case.  As a result, the toxicant transfer to the developing murine fetus is likely less than 
expected in singleton pregnancies.
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Direct exposure to 1 μmole/kg PCB 126 via oral gavage resulted in changes in 
gene expression similar to those in previous studies using TCDD for AhR activation.  
Ligand-activated AhR has consistently been shown to activate gene transcription of 
detoxifying enzymes Cyp1a1, Cyp1b1 and NQO1 as was confirmed in the current 
experiment [299, 308, 310, 320, 327-329]. Lipid metabolism was shown to be decreased 
with CPT1a, Plin2, ACC1 and Fasn.  This is inconsistent with previous studies using 
TCDD which showed increased lipid accumulation in mouse livers [308, 309, 316, 320,
330, 331].  However, Ovando et al demonstrated that fatty acid binding protein 5 (Fabp5) 
which is involved in fatty acid uptake, transport and metabolism, while it is upregulated 
in response to dioxin, it is not upregulated in response to PCB 126 [320].  The increase in 
GLUT1, HK3, and Pgk1 and concomitant attenuation of GLUT4, glucose-6-phosphate 
dehydogenase (G6pd), phosphorylase (pygl), LDHA, and glycogen synthase (GYS2) 
gene expression signifies modulation of carbohydrate metabolism.  These data suggest an 
increase in basal glucose uptake and phosphorylation.  G6pd is involved in shunting of 
glucose metabolism away from glycolysis and toward lipid synthesis or the pentose 
phosphate pathway [6, 23].  Its decreased gene expression in PCB-exposed animals 
suggests utilization of glucose for glycolysis while the decrease in LDHA and glycogen 
synthase point to increased utilization of glucose metabolites for mitochondrial 
respiration and not lactate production.  However, genes involved in monocarboxylate 
mitochondrial transport and metabolism were not included in the codesets.  Dere et al 
showed that TCDD-induced AhR activation increases AhR DNA binding at intragenic 
regions associated with lipid and carbohydrate metabolism at 2 and 24 hours after 
exposure [312]. Nonetheless, alterations in energy homeostasis in response to dioxin is 
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time-dependent, and there are no studies that evaluated changes in hepatic gene 
expression after 96 hour exposure in response to PCB 126 as in the current experiment.
Dioxin induced hepatic immune cell infiltration was reported by Boverhof et al. 
168 hours post exposure, corroborating the current observation of increased adhesion 
molecule expression [316].  Insulin-like growth factor binding protein 2 (Igfpb2) is 
decreased in both pregnant and non-pregnant mice directly exposed to PCB.  This is of 
importance because Igfbp2 is thought to mediate some of the glucose normalizing effects 
of leptin [332].  Additionally, Igfbp2 overexpression protects against high-fat-diet-
induced obesity, glucose intolerance, and insulin resistance. [333]. Hepatic Igfbp2 mRNA 
levels have been shown to correlate with circulating Igfbp2 levels and low serum Igfbp2 
are associated with obesity and insulin insensitivity [334-338].  The attenuated expression 
of Igfbp2 therefore serves as a mechanism of obesogenic activity of PCBs.  Obesity-
associated insulin resistance is also associated with inflammation and it is noteworthy 
that PCB exposure increased intercellular adhesion molecule (Icam1) expression 
independent of pregnancy.  
Fetal liver gene expression in response to in utero PCB exposure is as expected 
with regard to the classical increase in Cyp1a1, Cyp1b1, and NQO1.  Elevated expression 
of NQO1 in response to AhR activation has been shown to be dependent upon its binding 
to Nrf2.  Therefore, it is no surprise that Nrf2 is increased in response to PCB 126 
exposure as other Nrf2 responsive genes are also increased.  This experiment is the first 
to show increased hepatic Dpp4 expression upon PCB 126 exposure.  This may be an 
event particular to PCBs as many microarray studies using TCDD have not reported 
alterations in hepatic Dpp4 gene expression.  As Dpp4 degrades incretins such as GLP-1,
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increased Dpp4 expression could result in impaired oral glucose tolerance.  Incretins have 
a role in potentiating insulin secretion and increasing insulin sensitivity, so it would not 
be surprising to observe impairments in oral glucose tolerance as a result of perinatal 
PCB exposure.  
The 4 month old offspring perinatally exposed to PCB still exhibited augmented 
Cyp1a1 gene expression without detectable PCB in their livers although Cyp1b1 and 
NQO1 levels were comparable between treatment groups.  This phenomenon alludes to 
either an epigenetic modification at this particular locus permitting gene transcription in 
the absence of exogenous ligand or PCB-induced upregulation of the receptors unknown 
endogenous ligand.  Augmented CHOP and Atg7 gene expression is indicative of 
physiological stress, particularly stress of the endoplasmic reticulum.  Autophagy related 
proteins have been shown to be modulated by TCDD exposure in previous studies, but 
this is the first report of increased expression of transcriptionally regulated unfolded 
protein response protein, CHOP [339].  It could be the case that developmental exposure 
to PCB resulted in sustained oxidant production via xenobiotic detoxifying enzymes 
which caused eventual disrupted normal hepatic physiology.  Endoplasmic reticulum
stress has recently been shown to mediate some of the pathology associated with obesity 
and insulin resistance [340-347].
Also, in these aged offspring, again not taking into account gender, there is a 
significant decrease in Igf-1 expression.  Tijet et al showed decreased Igf-1 gene 
expression in mouse livers upon TCDD exposure and interestingly, this decrease was also 
demonstrated in wildtype mice compared to AhR null mice in the absence of ligand
[310]. So it is not entirely surprising that the current exposure model resulted in 
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attenuated Igf-1 gene expression in the absence of detectable ligand.  Decreased Igf-1
expression in utero can result in intrauterine growth restriction and poor growth during 
early life [348, 349].  It is intriguing that decreased Igf-1 expression was not observed in 
fetal livers, but only postnatally.  Postnatal growth is mediated not only by growth 
hormone, but also by Igf-1.  These male offspring, upon body composition analysis did 
exhibit decreased growth, specifically regarding lean mass, as the males weighed less and 
displayed decreased grams of lean mass while relative lean mass was unaltered (Tables 
2.3 and 2.5 in Chapter 2).
In conclusion, perinatal PCB exposure alters offspring gene expression in fetuses 
and 4 month old offspring.  These results illustrate the need to consider the ramifications 
of developmental xenobiotic exposure on liver physiology and gene expression and 
accentuate the pitfall of inferring effects of TCDD with those of all dioxin-like 
compounds.  Finally, further studies are needed to evaluate epigenetic and AhR 
coregulatory alterations that contribute to PCB-mediated effects on gene expression in 
the absence of detectable ligand within the context of developmental PCB exposure. 
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Table 4.1 s
Parameter Control
(n=9)
PCB
(n=9) p
Dam Body 
Weight (g)
57.22
(1.14)
57.58
(0.96) 0.810
Number of Pups 
per litter (g)
11.78
(0.32)
11.00
(0.47) 0.193
Fetal Body 
Weight (g)
1.210
(0.026)
1.258
(0.029) 0.226
Placental 
Weight (g)
0.095
(0.004)
0.107
(0.005) 0.066
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Table 4.2
Gene Control PCB PCB/control ratio P
IGFBP2 256.07 133.96 0.52 0.006
Plin2 790.91 528.69 0.67 0.044
LDHA 3103.82 2092.78 0.67 0.001
CPT-1A 781.70 549.31 0.70 <0.001
Acc1 96.26 70.96 0.74 0.048
SNAT2 376.16 292.17 0.78 0.004
426.90 333.57 0.78 0.002
eEF2 1597.35 1826.19 1.14 0.032
Eif3f 237.87 283.87 1.19 0.010
Cyp3a11 5755.76 7439.70 1.29 0.012
Rplp0 1459.02 1907.39 1.31 0.005
Cat 3288.02 4329.15 1.32 0.006
Pgk1 180.87 241.95 1.34 0.012
Dpp4 50.39 71.75 1.42 0.024
Hat1 14.84 22.35 1.51 0.030
Gpx1 1642.59 2526.97 1.54 <0.001
Icam1 22.06 35.07 1.59 <0.001
Gstm4 19.51 39.30 2.01 0.003
Nrf2 116.90 277.02 2.37 <0.001
Cyb5r1 3.91 10.55 2.70 0.031
Cyp1b1 13.83 40.30 2.91 <0.001
NQO1 8.43 28.19 3.35 0.001
MCP1 2.08 11.84 5.69 0.026
Gsta1 2.01 24.36 12.15 0.002
Cyp1a1 1.35 6265.34 4648.60 <0.001
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Table 4.3 -Pregnant 
Gene Control PCB PCB/ControlRatio p
GLUT4 76.98 14.47 0.19 0.010
G6pd2 135.04 36.61 0.27 0.015
fasn 10968.28 3253.73 0.30 <0.001
Acc1 2952.94 888.85 0.30 <0.001
G6pdx 581.57 186.37 0.32 0.022
IGFBP2 622.54 292.11 0.47 <0.001
GYS2 1290.93 848.91 0.66 0.011
Mecp2 48.37 36.05 0.75 0.049
PGC1a 83.92 63.73 0.76 0.008
Pygl 5736.99 4387.09 0.76 0.002
Eif3f 1565.58 1903.12 1.22 <0.001
Pgk1 910.35 1110.83 1.22 0.007
eEF2 8784.30 10807.17 1.23 0.002
Hprt1 95.25 118.61 1.25 0.012
Dpp4 898.49 1142.08 1.27 0.001
Tubb5 124.13 160.80 1.30 0.012
Gpx1 11491.81 14940.43 1.30 0.032
GLUT1 33.40 60.83 1.82 0.005
Hk3 48.64 97.40 2.00 0.005
Icam1 110.09 245.95 2.23 0.008
Nrf2 632.41 1450.06 2.29 <0.001
NQO1 97.96 250.12 2.55 <0.001
Cyp1b1 79.53 311.07 3.91 0.013
Cyp1a1 12.07 36241.14 3002.50 <0.001
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Table 4.4
Gene Control PCB PCB ratio p
LDHA 6524.58 4670.05 0.72 <0.001
GLUT1 420.59 330.55 0.79 0.045
Gapdh 3285.93 2699.88 0.82 0.004
GCR 197.48 165.98 0.84 0.031
B2m 2345.53 2689.96 1.15 0.018
242.99 280.12 1.15 0.044
SOD1 2652.56 3099.92 1.17 0.025
126.23 153.90 1.22 0.010
Prdx1 132.05 161.75 1.22 0.004
Dpp4 58.97 77.87 1.32 0.026
GSTM4 19.26 30.18 1.57 0.015
Nrf2 151.59 244.04 1.61 <0.001
NQO1 24.12 65.86 2.73 <0.001
Cyp1b1 11.36 44.50 3.92 0.002
Cyp1a1 1.30 3177.66 2444.82 <0.001
 
 
88
 
Table 4.5
Gene Control PCB PCB/control ratio p
Igf1 2129.19 1612.56 0.76 0.002
Hif1a 754.07 684.29 0.91 0.044
Atg7 462.78 515.69 1.11 0.028
CHOP 134.94 165.03 1.22 0.028
IGF1R 32.60 52.80 1.62 0.031
Cyp1a1 0.99 874.24 884.85 0.022
 
 
 
89
 
Table 4.6
Gene Control PCB PCB/control ratio p
Dnmt1 65.03 43.33 0.67 0.011
MCR 148.25 103.58 0.70 0.029
Igf1 2271.27 1785.08 0.79 0.040
FATP4 57.53 46.86 0.81 0.030
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Table 4.7
Gene Control PCB PCB/control ratio p
Hnf6 614.12 272.85 0.44 0.043
Igf1 2018.30 1474.18 0.73 0.027
Insr 1055.10 931.09 0.88 0.023
LRP1 6446.90 5668.68 0.88 0.048
Prdx1 1078.49 935.22 0.87 0.004
Pygl 9739.07 8686.65 0.89 0.044
Nrf2 1068.59 1304.09 1.22 0.017
Pparg 70.46 114.08 1.62 0.019
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Table 4.8 Primer Sequences for Real-Time PCR
Gene Primer Sequence
Cyp1a1 Fwd GAC TTC CAG CCT TCG TGT CA
Cyp1a1 Rev GGG TTC TTC CCC ACA GTC AG
NQO1 Fwd ACC CCA CTC TAT TTT GCT CC
NQO1 Rev ACT TAC TCC TTT TCC CAT CCT C
Cltc Fwd CAG TAA CAA CAA CCC AGA GAG
Cltc Rev TCA TAA GCA ACA CAA GCC AG
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Table 4.9 Real-Time PCR Validation of Hepatic Gene Expression
Relative Quantitya
Mean 
(SEM)
Gene Pregnant Non-pregnant Fetal
Male 
Offspring
Female 
Offspring
Cyp1a1
1940.10**
(470.65)
3761.74**
(1010.46)
3056.80***
(448.24)
177.64
(91.18)
72.30
(49.56)
NQO1
3.84***
(0.33)
2.02**
(0.28)
2.71***
(0.32)
2.94
(1.22)
0.71
(0.22)
a: Gene expression was calculated using 2- method with the mean of the control 
group serving as the calibrator
** indicates p<0.01
*** indicates p<0.001
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Table 4.10 Genes on 1st Codeset. Underline indicates a putative housekeeping gene and 
Bold indicates gene is not included in the other codeset.
Common Name Gene Symbol Gene Name
Acc1 Acaca Fatty acid synthase
Adipoq Adipoq Adiponectin
Adipor1 Adipor1 Adiponectin receptor 1
Adrenomedullin Adm Adrenomedullin
Ahr Ahr Aryl hydrocarbon receptor
Hif1b Arnt Aryl hydrocarbon receptor nuclear translocator
Bmal1 Arntl Brain and muscle ARNT-like protein 1
Aryl hydrocarbon receptor nuclear translocator-like
protein
ATF6 Atf6 Activating transcription factor 6
Atg7 Atg7 Autophagy related protein 7
B2m B2m beta-2 microglobulin
Bax Bax Bcl-2-associated X protein
Bcl2 Bcl2 B-cell lymphoma 2
Cat Cat Catalase
MCP1 Ccl2 Monocyte chemotractant protein-1
p16(INK4a) Cdkn2a Cyclin-dependent kinase inhibitor 2A
Cltc Cltc Clathrin heavy chain 1
CPT-1A Cpt1a Carnitine palmitoyltransferase 1A (liver)
Creb1 Creb1 CAMP responsive element binding protein 1
Cyb5r1 Cyb5r1 NADH-cytochrome b5 reductase 1
Aromatase Cyp19a1 Aromatase
Cyp1a1 Cyp1a1 Cytochrome P450, family 1, subfamily A, polypeptide 1
Cyp1b1 Cyp1b1 Cytochrome P450, family 1, subfamily B, polypeptide 1
Cyp3a11 Cyp3a11 Alpha-methyl acyl-CoA racemase
CHOP Ddit3 C/EBP homologous protein (CHOP)
DNA damage-inducible transcript 3
Dnmt1 Dnmt1 DNA methyl transferase 1
Dnmt3a Dnmt3a DNA methyl transferase 3a
Dnmt3b Dnmt3b DNA methyl transferase 3b
Dpp4/CD26 Dpp4 Dipeptidyl peptidase 4
eEF2 Eef2 Eukaryotic elongation factor 2
Eif3f Eif3f Eukaryotic translation initiation factor-3
Epx Epx Eosinophil peroxidase
Esr1 Esr1 Estrogen receptor alpha
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Table 4.10 (continued)
ERRa Esrra Estrogen-related receptor alpha
fasn Fasn Fatty acid synthase
Foxa2 Foxa2 forkhead box protein A2
Foxo1 Foxo1 forkhead box protein O1
G6pc G6pc Glucose-6-phosphatase, catalytic
Gapdh Gapdh Glyceraldehyde 3-phosphate dehydrogenase
Gck Gck Glucokinase
Gpx1 Gpx2 Glutathione peroxidase 1
Gsk3b Gsk3b Glycogen synthase kinase 3 beta
Gsta1 Gsta1 Glutathione S-transferase A1
Gstm4 Gstm4 Glutathione S-transferase mu 4
Gusb Gusb Beta-glucuronidase
GYS1 Gys1 Glycogen synthase 1
GYS2 Gys2 Glycogen synthase 2
Hat1 Hat1 Histone acetyltransferase 1
Hdac1 Hdac1 Histone deacetylase 1
Hdac3 Hdac3 Histone deacetylase 3
Hdac4 Hdac4 Histone deacetylase 4
HGF Hgf Hepatocyte growth factor
Hif1a Hif1a Hypoxia-inducible factor 1-alpha
Hprt1 Hprt Hypoxanthine-guanine phosphoribosyltransferase
BiP/Grp78 Hspa5 Binding immunoglobulin protein
heat shock 70 kDa protein 5
Icam1 Icam1 Intercellular adhesion molecule 1
IDE Ide Insulin-degrading enzyme
Ifng Ifng Interferon-gamma
Igf1 Igf1 Insulin-like growth factor 1
IGF1R Igf1r Insulin-like growth factor 1 receptor
Igfbp1 Igfbp1 Insulin-like growth factor-binding protein 1
IGFBP2 Igfbp2 Insulin-like growth factor-binding protein 2
Ikbkb Ikbkb Inhibitor of nuclear factor kappa-B kinase 
subunit beta
Il10 Il10 Interleukin-10
Il1a Il1a Interleukin-1a
Il1b Il1b Interleukin-1b
Il2 Il2 Interleukin-2
Il6 Il6 Interleukin-6
Insr Insr Insulin receptor
Irs1 Irs1 Insulin receptor substrate 1
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Table 4.10 (continued)
Irs2 Irs2 Insulin receptor substrate 2
KLF14 Klf14 Krüppel-like factor 14
LDHA Ldha Lactate dehydrogenase A
LDH B Ldhb Lactate dehydrogenase A
Lep Lep Leptin
Lipe Lipe Hormone-sensitive lipase
LRP1 Lrp1 Low density lipoprotein receptor-related protein 1
MafA / 
RIPE3b1 Mafa
V-maf avian musculoaponeurotic fibrosarcoma 
oncogene homolog A
c-MET/HGFR Met Met protooncogene
mtor Mtor Mammalian target of rapamycin
Nampt Nampt Nicotinamide phosphoribosyltransferase
Nfe2l2 Nfe2l2 Nuclear factor (erythroid-derived 2)-like 2
NQO1 Nqo1 NAD(P)H dehydrogenase [quinone] 1
PXR1 Nr1i2 Pregnane X receptor 1
GCR Nr3c1 Glucocorticoid receptor
Oit1/FAM3D Oit1 Family with sequence similarity 3, member D
PEPCK Pck1 Phosphoenolpyruvate carboxykinase
Pgk1 Pgk1 Phosphoglycerate kinase 1
cPLA2 Pla2g4a Cytosolic phospholipases A2
ZAC/PLAGL1 Plagl1 Zac tumor suppresor gene
Plin2 Plin2 Perilipin 2
Ppara Ppara Peroxisome proliferator-activated receptor alpha
Ppard Ppard Peroxisome proliferator-activated receptor delta
Pparg Pparg Peroxisome proliferator-activated receptor gamma
Ppargc1a Ppargc1a Peroxisome proliferator-activated receptor gamma 
coactivator 1-alpha
Prdx1 Prdx1 Peroxiredoxin-1
Prdx6 Prdx6 Peroxiredoxin-6
Ptgs2 Ptgs2 Prostaglandin-endoperoxide synthase 2
RCAN1 Rcan1 Regulator of calcineurin 1
Rela Rela V-rel reticuloendotheliosis viral oncogene 
homolog A
Rplp0/36B4 Rplp0 Ribosomal phosphoprotein, large, P0
Rxra Rxra Retinoid X receptor alpha
SHBG Shbg Sex hormone-binding globulin
SIRT1 Sirt1 Sirtuin 1
FATP1 Slc27a1 Fatty acid transport protein 1
FATP4 Slc27a4 Fatty acid transport protein 4
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Table 4.10 (continued)
GLUT1 Slc2a1 Glucose transporter 1
GLUT2 Slc2a2 Glucose transporter 2
GLUT4 Slc2a4 Glucose transporter 4
SNAT1 Slc38a1 Sodium-coupled neutral amino acid transporter 1
SNAT2 Slc38a2 Sodium-coupled neutral amino acid transporter 2
SOD1 Sod1 Superoxide dismutase 1
SOD3 Sod3 Superoxide dismutase 3
Opn Spp1 Osteopontin
TCF7L2 
variant 1
Tcf7l2 Transcription factor 7-like 2
Tnf Tnf Tumor necrosis factor alpha
Tubb5 Tubb5 Tubulin beta-4A chain
Txnrd2 Txnrd2 Thioredoxin reductase 2
UCP1 Ucp1 Uncoupling protein 1
Vcam1 Vcam1 Vascular cell adhesion protein 1
XBP1 Xbp1 X-box binding protein 1
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Table 4.11 Genes on 2nd codeset. Underline indicates a putative housekeeping gene and 
Bold indicates gene is not included in the other codeset.
Common Name Gene Symbol Gene Name
Acc1 Acaca Fatty acid synthase
Adipoq Adipoq Adiponectin
Adipor1 Adipor1 Adiponectin receptor 1
AFP Afp Alpha-fetoprotein
Ahr Ahr Aryl hydrocarbon receptor
Hif1b Arnt Aryl hydrocarbon receptor nuclear translocator
Bmal1 Arntl Brain and muscle ARNT-like protein 1
ATF6 Atf6 Activating transcription factor 6
Atg7 Atg7 Autophagy related protein 7
B2m B2m beta-2 microglobulin
Cat Cat Catalase
MCP1 Ccl2 Monocyte chemotractant protein-1
CHRNA7 Chrna7 Cholinergic receptor, nicotinic, alpha 7
Cltc Cltc Clathrin heavy chain 1
CPT-1A Cpt1a Carnitine palmitoyltransferase 1A (liver)
Creb1 Creb1 CAMP responsive element binding protein 1
Il8ra Cxcr1 Interleukin 8 receptor, alpha
IL8rb Cxcr2 Interleukin 8 receptor, beta
Cyb5r1 Cyb5r1 NADH-cytochrome b5 reductase 1
Cycs Cycs Cytochrome complex, somatic
Cyp1a1 Cyp1a1 Cytochrome P450, family 1, subfamily A, polypeptide 1
Cyp1b1 Cyp1b1 Cytochrome P450, family 1, subfamily B, polypeptide 1
Cyp3a11 Cyp3a11 Alpha-methyl acyl-CoA racemase
CHOP Ddit3 C/EBP homologous protein (CHOP)
DKK1 Dkk1 Dickkopf-related protein 1
Dnmt1 Dnmt1 DNA methyl transferase 1
Dnmt3a Dnmt3a DNA methyl transferase 3a
Dnmt3b Dnmt3b DNA methyl transferase 3b
Dpp4/CD26 Dpp4 Dipeptidyl peptidase 4
eEF2 Eef2 Eukaryotic elongation factor 2
Eif3f Eif3f Eukaryotic translation initiation factor-3
Estrogen 
receptor 1
Esr1 Estrogen receptor alpha
fasn Fasn Fatty acid synthase
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Table 4.11 (continued)
Fndc5 Fndc5 Fibronectin type III domain-containing protein 5
FoxA2 Foxa2 forkhead box protein A2
Foxo1 Foxo1 forkhead box protein O1
G6pc G6pc Glucose-6-phosphatase, catalytic
G6pd2 G6pd2 Glucose-6-phosphate dehydrogenase 2
G6pdx G6pdx Glucose-6-phosphate dehydrogenase X-linked
Gapdh Gapdh Glyceraldehyde 3-phosphate dehydrogenase
GBE1 Gbe1 Glycogen-branching enzyme
glucokinase Gck Glucokinase
Gckr Gckr Glucokinase regulatory protein
GLP1R Glp1r Glucagon-like peptide 1 receptor
Gpx1 Gpx1 Glutathione peroxidase 1
Gstm4 Gstm4 Glutathione S-transferase mu 4
Gusb Gusb Beta-glucuronidase
Gyg Gyg Glycogenin
GYS1 Gys1 Glycogen synthase 1
GYS2 Gys2 Glycogen synthase 2
Hat1 Hat1 Histone acetyltransferase 1
Hdac1 Hdac1 Histone deacetylase 1
Hdac3 Hdac3 Histone deacetylase 3
Hdac4 Hdac4 Histone deacetylase 4
HGF Hgf Hepatocyte growth factor
Hif1a Hif1a Hypoxia-inducible factor 1-alpha
Hk1 Hk1 Hexokinase-1
Hk2 Hk2 Hexokinase-2
Hk3 Hk3 Hexokinase-3
Hnf4a Hnf4a Hepatocyte nuclear factor 4 alpha
Hprt1 Hprt Hypoxanthine-guanine phosphoribosyltransferase
Hsd11b1 Hsd11b1 Hydroxysteroid 11-beta dehydrogenase 1
Hsd11b2 Hsd11b2 Hydroxysteroid 11-beta dehydrogenase 2
Icam1 Icam1 Intercellular adhesion molecule 1
IDE Ide insulin degrading enzyme
Ifng Ifng Interferon-gamma
Igf1 Igf1 Insulin-like growth factor 1
IGF1R Igf1r Insulin-like growth factor 1 receptor
Igf2 Igf2 Insulin-like growth factor 2
Igfbp1 Igfbp1 Insulin-like growth factor-binding protein 1
IGFBP2 Igfbp2 Insulin-like growth factor-binding protein 2
Il10 Il10 Interleukin-10
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Table 4.11 (continued)
Il1a Il1a Interleukin-1a
Il1b Il1b Interleukin-1b
Il6 Il6 Interleukin-6
Insr Insr Insulin receptor
Irs1 Irs1 Insulin receptor substrate 1
Irs2 Irs2 Insulin receptor substrate 2
LDHA Ldha Lactate dehydrogenase A
LDHB Ldhb Lactate dehydrogenase A
Lep Lep Leptin
Lipe Lipe Hormone-sensitive lipase
LRP1 Lrp1 Low density lipoprotein receptor-related protein 1
Mecp2 Mecp2 Methyl CpG binding protein 2
c-MET aka 
HGFR
Met Met protooncogene
mtor Mtor Mammalian target of rapamycin
Nfe2l2 Nfe2l2 Nuclear factor (erythroid-derived 2)-like 2
NOX1 Nox1 NADPH oxidase 1
NPY1R Npy1r Neuropeptide Y receptor type 1
NQO1 Nqo1 NAD(P)H dehydrogenase [quinone] 1
Lxra Nr1h3 Liver X receptor alpha
GCR Nr3c1 Glucocorticoid receptor
MCR Nr3c2 Mineralocorticoid receptor
Hnf6 Onecut1 Hepatocyte nuclear factor 6 alpha
PEPCK Pck1 Phosphoenolpyruvate carboxykinase
Pgk1 Pgk1 Phosphoglycerate kinase 1
Phkb Phkb Phosphorylase kinase, beta subunit
Phkg Phkg1 Phosphorylase kinase, gamma 1
Plin2 Plin2 Perilipin 2
Ppara Ppara Peroxisome proliferator-activated receptor alpha
Pparg Pparg Peroxisome proliferator-activated receptor gamma
Ppargc1a Ppargc1a Pparg coactivator 1-alpha
PRDM16 Prdm16 PR domain containing 16
Prdx1 Prdx1 Peroxiredoxin-1
Pygl Pygl Glycogen phosphorylase
RCAN1 Rcan1 Regulator of calcineurin 1
Rxra Rxra Retinoid X receptor alpha
SIRT1 Sirt1 Sirtuin 1
FATP1 Slc27a1 Fatty acid transport protein 1
FATP4 Slc27a4 Fatty acid transport protein 4
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Table 4.11 (continued)
GLUT1 Slc2a1 Glucose transporter 1
GLUT2 Slc2a2 Glucose transporter 2
GLUT3 Slc2a3 Glucose transporter 3
GLUT4 Slc2a4 Glucose transporter 4
SNAT1 Slc38a1 Sodium-coupled neutral amino acid transporter 1
SNAT2 Slc38a2 Sodium-coupled neutral amino acid transporter 2
SOD1 Sod1 Superoxide dismutase 1
SOD3 Sod3 Superoxide dismutase 3
Sox9 Sox9 SRY box-9
Sry Sry Sex determining region of chromosome Y
Tsp1 Thbs1 Thrombospondin 1
Tnf Tnf Tumor necrosis factor alpha
Tubb5 Tubb5 Tubulin beta-4A chain
Txnrd2 Txnrd2 Thioredoxin reductase 2
UCP1 Ucp1 Uncoupling protein 1
WNT3 Wnt3 Wingless-related MMTV integration site 3
WNT7a Wnt7a Wingless-related MMTV integration site 7a
XBP1 Xbp1 X-box binding protein 1
Zhx2 Zhx2 Zinc fingers and homeoboxes protein 2
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Figure 4.1.  Measurement of hepatic PCB 126 levels.  Graph illustrates quantity of PCB 
126 parent compound in the livers of non-pregnant, pregnant females, fetuses and 4 
month old offspring.  Lines represent mean and the standard error of the mean. Aged 
offspring n=16; all others n=9.
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Non-pregnant Pregnant
Fetal
Acc1
IGFBP2
eEF2
Eif3f
Pgk1
Gpx1
Icam1
LDHA
GSTM4
Gapdh
Dpp4
Nrf2
NQO1
Cyp1b1
Cyp1a1
GLUT4 
G6pd2
fasn
G6pdx
GYS2
Mecp2
PGC1
Pygl
Hprt1
Tubb5
GLUT1
Hk3
Plin2 
CPT-1A 
SNAT2 
Cyp3a11  
Rplp0
Cat
Hat1
Cyb5r1
MCP1
GSTA1
GLUT1
GCR
B2m 
Rxr
SOD1
Hif1
Prdx1
Figure 4.2 Venn diagram of genes differentially expressed in non-pregnant female mice, 
dams and E18.5 pups.  Genes are arranged in ascending order beginning with the genes 
most down regulated in PCB exposed animals and ending in those genes that are most 
upregulated.  Further, downregulated genes are underlined.  Bold italics indicates that 
genes were included in only one of the two codesets.
Copyright © Cetewayo Saif Rashid 2013
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CHAPTER 5
DISCUSSION
5.1. General Discussion
5.1.1. IUGR Biweekly exposure to 1 μmole/kg polychlorinated biphenyl (PCB) 
126 had no effect on the initial measurement of pup weight, which was at postnatal day 
(PND) 3, suggesting that gestational exposure to the pollutant did not restrict fetal 
growth.  I also mated the animals for 7 days to ensure copulation, but by doing so I
introduced a confounding factor in that it was impossible to determine the length of 
gestation which can clearly have an effect on offspring size.  Also, because we did not 
weigh the pups on PND 0, I cannot conclude for certain that birth weights were not 
different due to PCB exposure.  I corrected for these factors in AIM 3 by 1) allowing 
coitus for a single night, thus all conceptions were on the same day; and 2) measuring 
body weights at embryonic day 18 (E18) thereby nullifying variations in gestation length.  
Embryonic day 18 fetal weights were not different between groups, confirming the 
finding in AIM 1, that biweekly exposure to 1μmole/kg PCB 126 does not cause 
intrauterine growth restriction in my mouse model.  This of course is not to say that PCB 
exposure does not growth restrict the developing fetus as I only used one congener at a 
specific dosage. Nonetheless, there are findings in human studies that support that 
prenatal PCB exposure does not cause low birth weight [254].
Although the DOHaD hypothesis was predicated on changes of fetal growth and 
subsequent disease risk, it is now well accepted that fetal milieu modulation can affect 
offspring health irrespective of alterations in fetal growth.  Comparable fetal growth in 
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between treatment groups means that changes in divergent phenotypes with aging are not 
contingent upon decreased birth weight.  This adds to the impact of the presented 
research in that most births are of normal birth weight, and the majority of obese and 
diabetic individuals had normal birth weights. 
5.1.2 Body composition AIM 1 investigated the role of perinatal PCB exposure 
on offspring body weight and composition.  EchoMRI was first performed at 7 weeks of 
age at which time females from PCB exposed offspring showed dose-dependent increases 
in percent fat and reductions in percent lean mass while body weights were comparable 
between treatment groups.  This metabolically unfavorable profile was no longer 
statistically significant at 6 months of age even though the trend was still there regarding 
the 1 μmole/kg dose (T-Test p=0.089 and p=0.104 for percent lean and percent fat, 
respectively).  However, this decline in statistical significance continued.  These data are 
consistent with published data in humans that demonstrate increased adiposity in young 
and adolescent females exposed prenatally to PCBs [208, 239].  Moreover, the one 
investigation of prenatal PCB exposure on adult female obesity found no association, 
again corroborating the present data on a lack of effect of perinatal PCB exposure on 
aged females [242]. Interestingly, ovariectomized rodents exhibit similar changes in 
body composition as was observed in females born to PCB exposed dams at 7 weeks of 
age.  Particularly, ovariectomized rats have increased percent body fat and decreased 
percent lean mass [350, 351].  PCBs can modulate estrogen receptor activity [352, 353].
Because the effect on body composition in the females was only observed at the 7 week 
time point, when PCB body burden would have been greatest compared to the later time 
points, it is possible that the effects on body composition could have been secondary to 
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PCB disruption of estrogen activity thereby precipitating body composition profiles 
similar to those resulting from ovariectomization.  
The male offspring born to PCB-exposed dams displayed dose-dependent 
attenuation of lean mass and only trends toward decreased body weights.  Statistical 
comparison between vehicle exposed and the 1 μmole/kg PCB 126 groups only, showed 
significant reductions in body weight in addition to reductions in grams of lean mass for 
the duration of the study with no difference in fatness between groups meaning the 
reduction in lean mass in the male offspring is attributed solely to diminished lean mass.  
The lack of association between perinatal PCB exposure and obesity in male offspring is 
also supported by human studies that find significant associations only in female 
offspring.  The diminished lean mass is a novel finding that warrants further 
investigation.  The rate of childhood obesity is increasing alarmingly in America and 
perhaps perinatal PCB exposure is a contributing factor.  Cross-fostering studies should 
be conducted to determine whether in utero or lactational exposure precipitates these 
phenotypes.  Perhaps, supplementation of maternal or infant diet with protein can 
mitigate the reduction of lean mass.  Further, muscle biopsies can be taken for 
histological purposes to evaluate whether the reduction in lean mass is due to decreased 
muscle fiber number or size.  
5.1.3 Glucose tolerance AIM 2 investigated the role of perinatal coplanar PCB 
126 exposure on offspring glucose tolerance.  Interestingly the male offspring born to 
PCB-exposed dams exhibited impaired glucose tolerance upon an oral glucose tolerance 
test.  This impairment was not observed, however, at 3 months of age or later time points, 
suggesting disrupted glucose homeostasis was due to direct exposure of PCBs as aging
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would indeed decrease the body burden.  The fact that impaired glucose tolerance was 
not observed late in life also excludes a possibility of developmental programming of 
glucose intolerance as would be predicted by the DOHaD Hypothesis.  Animal studies 
have shown impaired glucose tolerance mediated by insulin resistance in male mice 
exposed to coplanar PCBs 77 and 126  [214].  Unfortunately an insulin tolerance test was 
not performed at this time so although likely, it is uncertain that PCB-induced impairment 
in glucose homeostasis was caused by insulin resistance.  Initially, it was thought that this 
impairment was a result of diminished lean mass, but in the present study, the body 
composition phenotype persisted while the impairment in glucose tolerance did not.
Experimentally, there were some factors that may compromise the glucose 
tolerance results in the males.  The male vehicle exposed offspring fought excessively 
and many had to be single-housed because of this.  The stress of fighting and being 
single-housed could have impacted the glucose tolerance results.  The PCB-treated males 
experienced delayed and more mild aggression resulting in unmatched housing 
conditions between groups.  Additionally, some of the vehicle treated males exhibited 
severe disruption of glucose homeostasis with 3 hour fasted glucose levels above 300 
mg/dL.  This observance, as I understand it via personal communication, is a very rare 
one.  Maternal ingestion of the safflower oil vehicle apparently disrupted glucose 
homeostasis in male offspring.  Several studies use corn oil as a vehicle, while others lace 
a cookie with PCB.  Perhaps these methods of PCB exposure should be used in future 
experiments in order to circumvent perinatal safflower oil-induced ablation of glucose 
homeostasis.
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Female offspring exhibited impaired glucose tolerance only upon aging, with the 
first observance of glucose intolerance being at 6 months of age.  This impairment 
persisted for the duration of the study which is suggestive of developmental
programming.  However, this impairment was most pronounced at the first time point of 
the glucose tolerance test, at 15 minutes.  This spike in blood glucose at 15 minutes and a 
rapid recovery is not characteristic of a glucose tolerance curve with insulin resistance or 
impaired insulin secretion.  A glucose tolerance test with i.p. administered glucose 
revealed comparable blood glucose regulation.  These data suggest that PCB-mediated 
attenuation of glucose tolerance was not due to glucose-stimulated insulin secretion.  
Further, insulin tolerance tests demonstrated similar rates of decline of blood glucose 
between vehicle and perinatal PCB-exposed female offspring, thus confirming the 
absence of insulin resistance.  An early event in glucose appearance may have been 
mediating the effects such as increased rate of gastric emptying, portal vein shunting by 
the ductus venosus, impaired first pass hepatic glucose uptake, delayed hepatic glucose 
production inhibition, or incretin dysfunction.  The pyruvate tolerance test demonstrated 
no difference in hepatic glucose output via gluconeogenesis.  The glucagon-like peptide 
(GLP) -1 receptor antagonism study is inconclusive as it was not controlled for properly 
due to low number of animals remaining and so should be repeated with larger sample 
size.  In addition to repeating the GLP-1 receptor antagonism study, GLP-1 receptor 
agonist Exendin-4 should be used to further evaluate the involvement of this incretin in 
the observed phenotype.  Future studies should also use a different vehicle because it is 
likely safflower oil had an effect on the female offspring because of the profound effects 
on males.  A paraceptamol gastric emptying test could be performed to investigate if 
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different rates of gastric emptying are causing the increase in blood glucose at the early 
15 minute time point.  Cross fostering experiments again would aid in determining the 
significance of in utero versus postnatal exposure.  Because poor diet is prevalent in 
developed countries and causal for obesity and diabetes, I propose weaning the a subset 
of the offspring onto a Western Diet determine if this exacerbates either PCB-induced 
obesity or impaired glucose tolerance.  
5.1.4 Hepatic gene expression Absolute quantification of mRNA of liver tissue 
from vehicle and PCB treated pregnant and non-pregnant dams, E18 fetuses and 4 month 
old male and female offspring was measured using NanoString nCounter technology.  
The goal was not to make a direct comparison between PCB-induced effects during 
pregnancy versus those female mice that were not impregnated so as to investigate the 
effect of pregnancy on PCB-induced modulation of hepatic gene expression, therefore, 
two-way ANOVA’s were not performed. The goal was to uncover possible mechanisms 
involved in disruption of glucose homeostasis as a result of maternal PCB exposure.
Insulin-like growth factor binding protein 2 (IGFBP2) has been shown to play a role in 
both development of obesity and glucose tolerance evidenced by attenuated development 
of age and diet associated obesity and glucose intolerance in human-IGFBP2 
overexpressing mice [333].  The decreased IGFBP2 gene expression was observed in 
PCB exposed female mice, indicating susceptibility to both obesity and perturbed glucose 
regulation.  Further, euglycemic clamp studies reveal that IGFBP2 improves hepatic 
insulin sensitivity [334].  Moreover, increased dipeptidyl peptidase 4 (DPP4) expression 
in female livers, fetal livers, and the interaction of Dpp4 with gender reveal susceptibility 
of females to the glucoregulatory effects of incretins (reviewed in [322] and [323]).
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DPP4 degrades incretins, and by reducing systemic levels, their beneficial effects may be 
compromised.  These female specific changes in gene expression illustrate a role of PCBs 
in both obesogenicity and oral glucose intolerance. Finally, aged offspring displayed 
increased expression of endoplasmic reticulum stress response proteins DNA damage-
inducible transcript 3 (CHOP) and autophagy related protein 7 (Atg7).  Obesity causes
chronic ER stress in liver and other tissues in humans and animal models [340-342].
Recent evidence demonstrates a role of ER stress in propagating metabolic derangements, 
and mitigation of ER stress has been shown to improve insulin sensitivity and glycemic 
control [341, 343-347].  The putative mechanism is that ER stress signaling causes c-Jun 
N-terminal Kinase (JNK) activation which attenuates insulin signal transduction and 
consequently insulin sensitivity [354-356].  However, the present study only showed 
increases in two ER stress-related gene transcripts.  The activities of many ER stress 
proteins such as X-box-binding protein-1 (Xbp1) and activating transcription factor 
(ATF) 6 are not transcriptionally regulated, therefore future studies should utilize 
immunohistochemical techniques to further elucidate the extent of PCB-programmed ER 
stress, as well as Western blotting for phosphorylated JNK and components of insulin 
signaling.
A role of dioxins in gut homeostasis is emerging.  The immune system of the gut 
plays a major role in whole body immunity as many foreign particles are ingested yet do 
not elicit immune response.  Also, the gut is home to over a trillion commensal bacteria 
whose presence in the blood stream can cause many disorders including sepsis and death.  
The AhR is expressed abundantly in intestinal epithelial cells and may play a role in oral 
tolerance and gut barrier maintenance [357, 358]. Moreover, toll-like receptors that 
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recognize bacterial components have been shown to be involved in energy homeostasis 
[359].  Research also shows that the composition of the gut microbiome can predispose 
the host to obesity [360, 361].  Just this year, Choi et al. has shown that PCB ingestion 
alters the gut microflora to one which is metabolically unfavourable; the study also 
showed that exercise can attenuate the observed negative changes in bacterial 
composition [362].
5.1.5 Limitations One limitation of the presented research is that only one toxicant 
was used.  Humans are exposed to a plethora of dietary xenobiotic compounds.  Toxic 
equivalency factors are AhR binding affinities relative to dioxin and are used to provide 
an estimation of AhR-mediated toxicity.  However, some xenobiotics do not bind the 
AhR but still mediate toxicological effects. Another limitation is that my exposure model 
is not consistent with the human experience in that humans have chronic low level 
exposure over many years that produce reported body burdens while my model used an 
acute exposure model in order to decrease body burden variability and expedite the 
findings. Because my dissertation is focused on perinatal effects of PCBs on offspring 
body composition and glucose tolerance, experimental animals were not exposed to PCBs 
after weaning.  However, feeding the offspring a Western diet containing PCBs would 
more precisely mimic dietary exposure seen in humans and perhaps the results would 
provide for better extrapolation.  
Copyright © Cetewayo Saif Rashid 2013
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Appendix
Pilot Study
Introduction: The experiments presented in this dissertation investigates the effects of 
maternal PCB exposure on offspring body composition and glucose tolerance and further, 
investigates changes in hepatic gene expression.  Before experiments were performed, 
there was a selection of dosage that occurred.  Here I present data regarding the selection 
of our dose and the frequency of dosing.  The dosing was selected based upon systemic 
inflammation occurring as a result of PCB exposure.  Further, a preliminary study 
investigated the effects of maternal PCB exposure on fecundity.
Materials and Methods: The experiments were performed in accordance with an 
approved Institutional Animal Care and Use Committee protocol at the University of 
Kentucky. ICR/CD-1 mice were purchased from Taconic.  In selection of my dose, mice 
were oral gavaged with either tocopherol-stripped safflower oil (Dyets # 403952 
Bethlehem, PA) or PCB 126 (3, 3’, 4, 4’, 5-pentachlorobiphenyl from AccuStandard C-
126N, New Haven, CT).  Concentrations of 0, 1, and 5 μmole/kg PCB 126 was 
administered to female ICR mice via oral gavage and serum was collected either 24 hours 
or one week post exposure in separate cohorts.  Serum cytokine levels were measured 
using Bio-Plex Pro Mouse Cytokine 23-Plex Panel (Bio-rad M60-009RDPD).  Based 
upon the findings regarding PCB-induced inflammation, a preliminary study was 
conducted to investigate their effects on fecundity.  Naïve females were purchased from 
Taconic and acclimated for one week prior to PCB exposure.  Female mice were orally 
gavaged with either vehicle (tocopherol-stripped safflower oil) or PCB 126 at 
concentrations of 1 and 5 μmole/kg beginning 2 weeks prior to mating.  This exposure 
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was repeated weekly for a total of 5 doses.  The frequency was such that mice were 
exposed twice prior to mating, once at the commencement of mating, and twice again 
during gestation.  Mice were not exposed during lactation.  Oneway ANOVA was 
performed to test for statistical significance.
Results
Exposure to PCB 126 resulted in an acute inflammatory response with proinflammatory 
cytokines, TNF- -1 and Il-6, being elevated 24 hours after exposure but not at one 
week post exposure although these effects were not statistically significant (Figure S.1A-
C).   Because the inflammatory response appeared to be mitigated after one week, I 
exposed mice weekly to PCB.  Weekly PCB exposure had dire effects on fecundity and 
rearing with PCB exposure affecting the number of pregnancies, and PND 2 litter 
number, size and mean body weight (Table S.1).  On PND 28, at which time mice were 
weaned, there was a marked effect on body size specifically in the male offspring (Figure 
S.1D). 
Discussion
This weekly dosing appeared to cause overt toxicity which was not my goal.  My goal is 
to investigate subtle changes in PCB exposure on offspring metabolic parameters.  These 
effects on offspring health were not conducive to subsequent experimentation due to its 
confounding effect on survival.  As a result, PCB exposure was lessened in frequency. 
Also the 5 μmole/kg dose was removed from any further experimentation.
 
 
113
 
Table S.1 Pilot Study: Weekly PCB Exposure on Fecundity and Survival
*, ** significantly different from control, p<0.05 and p<0.01, respectively.
a: Number of pregnancies based upon litter delivery 
b: One of these pregnancies is based on body weight gain and not litter delivery
Dose of 
PCB 126 
(μmole/kg)
#a
Pregnancies
Postnatal Day 2
Mean
(SEM)
# litters Pups/litter Body weight
0 19/20 19 10( 0.485)
2.207
(0.056)
1 17/19 6 3.5*(0.428)
1.967
(0.163)
5 3/18b 1 5(0.000)
2.560
(0.000)
P - - 0.002 0.032
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Figure S.1 Effect of PCB exposure on inflammation and offspring size. In selection of 
a dose, PCB 126 or vehicle was administered to female ICR mice via oral gavage.  Serum 
cytokine levels were measured 24 hours after exposure and one week post exposure in 
separate cohorts.  A-C show the amount of inflammatory cytokines in serum as fold 
change to vehicle exposed animals.  The p values were determined via Oneway ANOVA. 
D is a picture showing the size difference among male offspring between treatment 
groups at weaning, which was at PND 28.
Copyright © Cetewayo Saif Rashid 2013
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Much of the data and text from Chapter 2 is “Reprinted from Journal of Pediatric 
Biochemistry, vol. 3 , Rashid CS, Carter LG, Hennig B, Pearson KJ. Perinatal 
polychlorinated biphenyl 126 exposure alters offspring body composition, 47-53,
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